events.economist.com
Open in
urlscan Pro
2606:4700:4400::6812:21b3
Public Scan
URL:
https://events.economist.com/future-of-healthcare-week/agenda/?RefID=Tacttree&utm_source=email&utm_medium=Tacttree&utm_campai...
Submission: On November 07 via manual from US — Scanned from DE
Submission: On November 07 via manual from US — Scanned from DE
Form analysis 0 forms found in the DOM
Text Content
Share this event
bar1 bar2 bar3
Menu
* Home
* Speakers
* Agenda
* Sponsors
* Sponsors
* Why sponsor
* Insight hours
* Insight hour (Oct 20th)
* Insight hour (Nov 11th)
* Event information
* Venue
* Contact us
* Refer a colleague
* 2021 delegate list
* Register now
* Become a sponsor
AGENDA
* Tuesday November 15th 2022 (LIVE from Singapore): Healthcare systems and
provisions
* Wednesday November 16th 2022 (LIVE from Singapore): Disease trends and
prevention
* Thursday November 17th 2022: Innovations: digital, genomic and green
healthcare
* Full Day
* Plenary
Plenary
8:00 am -9:00 SGT
PRIVATE ROUNDTABLE - PERSONALISED HEALTHCARE AT SCALE: TECHNOLOGY LESSONS FOR
EQUITY POST-PANDEMIC
This roundtable will convene healthcare leaders to discuss how to maximise and
extend the novel use of health technology and communication strategies that was
accelerated by the pandemic to push for more digital transformation and foster
access to healthcare.
Apply to attend as a participant here.
MODERATED BY
* View Profile
EMILY TIEMANN
Manager, health practice, Economist Impact
bar1 bar2
EMILY TIEMANN
Manager, health practice, Economist Impact
November 15th 2022
* 08:00 am -9:00
Private roundtable - Personalised healthcare at scale: technology lessons
for equity post-pandemic
* 04:30 pm -5:10
Enabling the patient voice
November 16th 2022
* 12:05 pm -12:50
Concurrent: Women’s health: building a roadmap for equity
* 02:50 pm -3:35
Healthspan over lifespan: mitigating the diseases of ageing
Emily Tiemann is a Health Practice Manager in the Policy and Insights team at
Economist Impact in Singapore, where she is involved in projects ranging from
Breast Cancer, Fertility and Digital Health. Prior to this, she worked in
policy at the HFEA, the UK’s fertility regulator, leading projects related to
consent, the Code of Practice and clinic inspections. She also worked closely
with the Department of Health to outline the new upcoming legislation related
to extending the storage periods of gametes and embryos beyond 10 years.
Emily started her career as an embryologist at fertility clinics carrying out
diagnostic and micromanipulation procedures. Emily has a degree in Biology
from McGill University in Canada and a Master’s degree in Women’s Health from
University College London.
8:00 am -9:00 SGT
REGISTRATION AND COFFEE
9:00 am -9:10 SGT
WELCOME AND OPENING REMARKS
9:10 am -9:35 SGT
MINISTERIAL KEYNOTE INTERVIEW: A VIEW FROM INDONESIA
* View Profile
BUDI GUNADI SADIKIN
Minister of Health, Indonesia
bar1 bar2
BUDI GUNADI SADIKIN
Minister of Health, Indonesia
November 15th 2022
* 09:10 am -9:35
Ministerial keynote interview: a view from Indonesia
Budi Gunadi Sadikin was appointed minister of health in December 2020. He is
assigned to lead the covid-19 vaccination programme for Indonesia and improve
health services in the country. Previously Mr Sadikin was the vice minister I
of state-owned enterprises and led the National Economic Recovery and
Transformation Task-Force. From 2017 to 2019 he was the group chief executive
of the mining industry holding company Indonesia Asahan Aluminium. He served
as senior adviser to the minister of state-owned enterprises from 2016 to
2017.
Mr Sadikin began his career in 1988 as an information technology officer at
IBM’s Asia-Pacific headquarters in Tokyo. He worked at IBM until 1994,
culminating in his position as manager of systems integration professional
services. Subsequently, he worked for Bank Bali until 1999 and held various
managerial roles, including general manager of human resources.
Mr Sadikin then moved to ABN AMRO Bank Indonesia and remained there until
2004. His last position at the bank was director of consumer and commercial
banking (senior vice-president) for ABN AMRO Bank Indonesia and Malaysia. He
then joined Bank Danamon as the head of consumer banking (executive
vice-president) and later the director of Adira Quantum Multi Finance. In
2006 he joined Bank Mandiri as the director of micro retail banking. He
served as president director of Bank Mandiri from 2013 to 2016.
MODERATED BY
* View Profile
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
bar1 bar2
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
November 15th 2022
* 09:10 am -9:35
Ministerial keynote interview: a view from Indonesia
* 09:40 am -9:55
Spotlight interview
* 10:05 am -10:20
Exclusive keynote: Future of healthcare outlook
* 10:25 am -11:10
Panel: Removing silos—collaborating for success in health
* 11:45 am -12:30
Incentivising health: fostering value-based care
* 01:50 pm -2:35
Elevating access: financing health and universal healthcare
* 02:40 pm -3:05
Keynote interview
November 16th 2022
* 10:00 am -10:45
Balancing lives and livelihoods: preparedness for future pandemics in the
aftermath of covid-19
* 10:50 am -11:35
Jabs for the jab-nots: the future of open-source vaccines, mRNA and beyond
* 02:00 pm -2:45
Concurrent: The future of cancer care
David Humphreys is the global practice leader, health policy, Economist
Impact. He leads a multidisciplinary team that conducts high quality clinical
and policy analyses to inform micro level health decision making and produce
macro level perspectives. Supporting clients across the health ecosystem for
internal and external strategy making, David develops and directs engagements
on such issues as evidence-based reviews of new health technologies, future
healthcare challenges, value-based healthcare approaches for specific
therapeutic areas, and impact of new policy initiatives.
Previously, David held multiple roles at The EIU, first as the Americas
Director of Custom Research managing a business that delivered projects on
public policy and market strategy, and then as the Head of EIU Healthcare in
the US. Prior to joining The EIU, he was the senior director of Latin America
at Frost & Sullivan, where he led strategic analyses in industries such as
ICT and Healthcare, and spearheaded the firm’s expansion into the region. He
also served as a senior adviser at Management Partners, a consulting firm for
municipal governments in the US.
David holds an MBA degree and an honours certificate in international
business diplomacy from Georgetown University, and a BA in economics from
Ohio Wesleyan University. He has participated as a speaker at various
healthcare conferences, given lectures at academic institutions, led
strategic workshops and directed numerous expert panels with senior level
executives.
9:40 am -9:55 SGT
SPOTLIGHT INTERVIEW
* View Profile
CLAIR DEEVY
Global director of social impact, WhatsApp
bar1 bar2
CLAIR DEEVY
Global director of social impact, WhatsApp
November 15th 2022
* 09:40 am -9:55
Spotlight interview
Clair Deevy was appointed global director of the newly formed WhatsApp social
impact team in early 2022. In this role she leads strategy development and
execution for programmes and partnerships across areas such as health, crisis
response, digital literacy and charitable giving.
Working in policy, communications and community partnerships for more than 20
years, Ms Deevy’s professional and volunteer experience includes government,
NGOs, private sector and corporate foundations, and experience across digital
and financial literacy, community engagement, women’s empowerment, and
creating partnerships for positive social impact.
With Meta since 2015, Ms Deevy has held roles as WhatsApp director of public
policy APAC and Facebook director of community affairs for APAC and LATAM.
Previously, she led Microsoft’s corporate social responsibility programmes in
APAC.
Ms Deevy holds a bachelor of applied science in environmental management and
a master of management, and she is a qualified partnership broker. From 2014
to 2017 she was appointed an ambassador for women in technology for the
Singapore committee of UN Women.
MODERATED BY
* View Profile
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
bar1 bar2
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
November 15th 2022
* 09:10 am -9:35
Ministerial keynote interview: a view from Indonesia
* 09:40 am -9:55
Spotlight interview
* 10:05 am -10:20
Exclusive keynote: Future of healthcare outlook
* 10:25 am -11:10
Panel: Removing silos—collaborating for success in health
* 11:45 am -12:30
Incentivising health: fostering value-based care
* 01:50 pm -2:35
Elevating access: financing health and universal healthcare
* 02:40 pm -3:05
Keynote interview
November 16th 2022
* 10:00 am -10:45
Balancing lives and livelihoods: preparedness for future pandemics in the
aftermath of covid-19
* 10:50 am -11:35
Jabs for the jab-nots: the future of open-source vaccines, mRNA and beyond
* 02:00 pm -2:45
Concurrent: The future of cancer care
David Humphreys is the global practice leader, health policy, Economist
Impact. He leads a multidisciplinary team that conducts high quality clinical
and policy analyses to inform micro level health decision making and produce
macro level perspectives. Supporting clients across the health ecosystem for
internal and external strategy making, David develops and directs engagements
on such issues as evidence-based reviews of new health technologies, future
healthcare challenges, value-based healthcare approaches for specific
therapeutic areas, and impact of new policy initiatives.
Previously, David held multiple roles at The EIU, first as the Americas
Director of Custom Research managing a business that delivered projects on
public policy and market strategy, and then as the Head of EIU Healthcare in
the US. Prior to joining The EIU, he was the senior director of Latin America
at Frost & Sullivan, where he led strategic analyses in industries such as
ICT and Healthcare, and spearheaded the firm’s expansion into the region. He
also served as a senior adviser at Management Partners, a consulting firm for
municipal governments in the US.
David holds an MBA degree and an honours certificate in international
business diplomacy from Georgetown University, and a BA in economics from
Ohio Wesleyan University. He has participated as a speaker at various
healthcare conferences, given lectures at academic institutions, led
strategic workshops and directed numerous expert panels with senior level
executives.
10:05 am -10:20 SGT
EXCLUSIVE KEYNOTE: FUTURE OF HEALTHCARE OUTLOOK
Exclusively for in-person attendees
MODERATED BY
* View Profile
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
bar1 bar2
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
November 15th 2022
* 09:10 am -9:35
Ministerial keynote interview: a view from Indonesia
* 09:40 am -9:55
Spotlight interview
* 10:05 am -10:20
Exclusive keynote: Future of healthcare outlook
* 10:25 am -11:10
Panel: Removing silos—collaborating for success in health
* 11:45 am -12:30
Incentivising health: fostering value-based care
* 01:50 pm -2:35
Elevating access: financing health and universal healthcare
* 02:40 pm -3:05
Keynote interview
November 16th 2022
* 10:00 am -10:45
Balancing lives and livelihoods: preparedness for future pandemics in the
aftermath of covid-19
* 10:50 am -11:35
Jabs for the jab-nots: the future of open-source vaccines, mRNA and beyond
* 02:00 pm -2:45
Concurrent: The future of cancer care
David Humphreys is the global practice leader, health policy, Economist
Impact. He leads a multidisciplinary team that conducts high quality clinical
and policy analyses to inform micro level health decision making and produce
macro level perspectives. Supporting clients across the health ecosystem for
internal and external strategy making, David develops and directs engagements
on such issues as evidence-based reviews of new health technologies, future
healthcare challenges, value-based healthcare approaches for specific
therapeutic areas, and impact of new policy initiatives.
Previously, David held multiple roles at The EIU, first as the Americas
Director of Custom Research managing a business that delivered projects on
public policy and market strategy, and then as the Head of EIU Healthcare in
the US. Prior to joining The EIU, he was the senior director of Latin America
at Frost & Sullivan, where he led strategic analyses in industries such as
ICT and Healthcare, and spearheaded the firm’s expansion into the region. He
also served as a senior adviser at Management Partners, a consulting firm for
municipal governments in the US.
David holds an MBA degree and an honours certificate in international
business diplomacy from Georgetown University, and a BA in economics from
Ohio Wesleyan University. He has participated as a speaker at various
healthcare conferences, given lectures at academic institutions, led
strategic workshops and directed numerous expert panels with senior level
executives.
10:25 am -11:10 SGT
PANEL: REMOVING SILOS—COLLABORATING FOR SUCCESS IN HEALTH
Healthcare as an industry has historically been siloed and fragmented, within
and between organisations. Vaccine nationalism and political obstacles were
barriers to optimal joint efforts during the covid-19 crisis. A more cohesive
partnership and collaboration ecosystem needs to be developed that brings
multiple stakeholders such as government, industry and the civil sector closer
together along with other innovators such as technologists. For example,
researchers and start-ups work to identify use cases and build sustainable tech
solutions, while enablers such as policymakers and financiers help fund,
promote, scale and encourage these tech innovators. However, there are numerous
gaps between the needs of innovators driving technological progress and the
priorities of enablers. This extends to other innovations in healthcare.
The pandemic did catalyse cross-sector collaboration in a substantial way—so how
can momentum around sharing data and breaking down silos now be maintained? What
should leaders be doing to encourage organisational de-siloing? Can the public,
private and civil sectors across health and technology come together to create a
unified system? How can organisations maximise the opportunities that
public-private partnerships present? What are the major challenges in building
new coalitions and reforming systems and policies that produce inequities in
healthcare? What role does global health governance play here, and which key
stakeholders should be held to account? Where are we in the negotiations towards
a WHO pandemic treaty, which began in December 2021, seeking to codify the
collaboration gains borne out of the pandemic?
* View Profile
LOW CHENG OOI
Chief technology officer, Sheares Healthcare Management and Senior advisor,
CMIO Office, Ministry of Health, Singapore
bar1 bar2
LOW CHENG OOI
Chief technology officer, Sheares Healthcare Management and Senior advisor,
CMIO Office, Ministry of Health, Singapore
*
November 15th 2022
* 10:25 am -11:10
Panel: Removing silos—collaborating for success in health
* View Profile
JOHN EYRES
Director, Office of Public Health and Education, USAID Cambodia
bar1 bar2
JOHN EYRES
Director, Office of Public Health and Education, USAID Cambodia
November 15th 2022
* 10:25 am -11:10
Panel: Removing silos—collaborating for success in health
* View Profile
SANIA NISHTAR
Cardiologist and member of the Senate, Pakistan
bar1 bar2
SANIA NISHTAR
Cardiologist and member of the Senate, Pakistan
*
*
November 15th 2022
* 10:25 am -11:10
Panel: Removing silos—collaborating for success in health
Sania Nishtar is a member of the Senate (upper house of parliament) of
Pakistan. From 2019 to May 2022, she served as special assistant to the prime
minister of Pakistan and federal minister and held the cabinet portfolio of
poverty alleviation. Senator Nishtar founded Ehsaas, the government’s
flagship social protection programme, and led its implementation. She also
chaired the Benazir Income Support Programme during that time.
Senator Nishtar is former chair of several multilateral initiatives: the
World Health Organisation (WHO) High-Level Commission on Non-communicable
diseases, World Economic Forum Global Agenda Council on the Future of Health
Care, US National Academy of Sciences global study on the quality of health
care in low- and middle-income countries, advisory committee of the UN
International Institute for Global Health, UN secretary-general’s Independent
Accountability Panel for Women’s and Children’s Health and WHO Commission on
Ending Childhood Obesity.
She is founder of the non-governmental organisation Heartfile and has
received many international awards for her work. She is also widely
published. In 2017, she was Pakistan’s nominee for director-general of the
WHO and was in the final shortlist of three.
Senator Nishtar graduated at the top of her class in 1986. She is a fellow of
the Royal College of Physicians and took a PhD at King’s College London. She
was honoured with a doctorate in science, honoris causa, in 2019.
* View Profile
SYARU SHIRLEY LIN
Chair, Center for Asia-Pacific Resilience and Innovation (CAPRI) and Research
Professor, Miller Center of Public Affairs, University of Virginia
bar1 bar2
SYARU SHIRLEY LIN
Chair, Center for Asia-Pacific Resilience and Innovation (CAPRI) and Research
Professor, Miller Center of Public Affairs, University of Virginia
*
*
*
November 15th 2022
* 10:25 am -11:10
Panel: Removing silos—collaborating for success in health
Syaru Shirley Lin is a Research Professor at the Miller Center of Public
Affairs at the University of Virginia, a Non-Resident Senior Fellow at the
Brookings Institution, and an Adjunct Professor at the Chinese University of
Hong Kong. She has founded a new international think tank based in Taipei and
Charlottesville, the Center for Asia-Pacific Resilience and Innovation
(CAPRI), which conducts interdisciplinary, comparative research on innovative
policies that can strengthen resilience and improve governance in the Asia
Pacific. CAPRI currently focuses on enhancing resilience at the intersection
of health, economic growth, and environmental sustainability. Professor Lin
retired as a partner at Goldman Sachs, where she spearheaded the firm’s
investments in many technology start-ups and was a founding board member of
Alibaba Group and Semiconductor Manufacturing International Corporation.
Prior to her work in private equity and venture capital, she specialized in
the privatization of state-owned enterprises in China, Taiwan and Singapore.
Professor Lin’s present board service includes TE Connectivity, Goldman Sachs
Asia Bank and Langham Hospitality Investments. She serves on the board of the
Virginia-based Focused Ultrasound Foundation and is an advisor to the
Taiwan-U.S. Talent Circulation Alliance. Professor Lin graduated cum laude
from Harvard College and earned her masters and Ph.D. from the department of
politics and public administration at the University of Hong Kong.
MODERATED BY
* View Profile
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
bar1 bar2
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
November 15th 2022
* 09:10 am -9:35
Ministerial keynote interview: a view from Indonesia
* 09:40 am -9:55
Spotlight interview
* 10:05 am -10:20
Exclusive keynote: Future of healthcare outlook
* 10:25 am -11:10
Panel: Removing silos—collaborating for success in health
* 11:45 am -12:30
Incentivising health: fostering value-based care
* 01:50 pm -2:35
Elevating access: financing health and universal healthcare
* 02:40 pm -3:05
Keynote interview
November 16th 2022
* 10:00 am -10:45
Balancing lives and livelihoods: preparedness for future pandemics in the
aftermath of covid-19
* 10:50 am -11:35
Jabs for the jab-nots: the future of open-source vaccines, mRNA and beyond
* 02:00 pm -2:45
Concurrent: The future of cancer care
David Humphreys is the global practice leader, health policy, Economist
Impact. He leads a multidisciplinary team that conducts high quality clinical
and policy analyses to inform micro level health decision making and produce
macro level perspectives. Supporting clients across the health ecosystem for
internal and external strategy making, David develops and directs engagements
on such issues as evidence-based reviews of new health technologies, future
healthcare challenges, value-based healthcare approaches for specific
therapeutic areas, and impact of new policy initiatives.
Previously, David held multiple roles at The EIU, first as the Americas
Director of Custom Research managing a business that delivered projects on
public policy and market strategy, and then as the Head of EIU Healthcare in
the US. Prior to joining The EIU, he was the senior director of Latin America
at Frost & Sullivan, where he led strategic analyses in industries such as
ICT and Healthcare, and spearheaded the firm’s expansion into the region. He
also served as a senior adviser at Management Partners, a consulting firm for
municipal governments in the US.
David holds an MBA degree and an honours certificate in international
business diplomacy from Georgetown University, and a BA in economics from
Ohio Wesleyan University. He has participated as a speaker at various
healthcare conferences, given lectures at academic institutions, led
strategic workshops and directed numerous expert panels with senior level
executives.
11:10 am -11:40 SGT
COFFEE BREAK
11:45 am -12:30 SGT
INCENTIVISING HEALTH: FOSTERING VALUE-BASED CARE
The Asia-Pacific region is diverse and complex, with approximately 60% of the
world’s people. Ageing populations, falling fertility and growing morbidity
rates, increasing urbanisation and significant migration flows create further
complexity along with rising costs and a surging demand for healthcare. It has
recently been announced that Singapore will move away from a fee-for-service
model and towards capitation funding, to steer healthcare clusters towards care
based on outcomes and value. In a system that historically incentivises curative
over preventive care, where can value-based care realign incentives among key
stakeholders? Which organisations are making inroads here? How can healthcare
providers reduce the cost of care without surrendering quality? How can complex
non-communicable diseases and chronic issues be covered sustainably?
* View Profile
JEREMY LIM
Director, Leadership Institute for Global Health Transformation, Saw Swee
Hock School of Public Health, National University of Singapore
bar1 bar2
JEREMY LIM
Director, Leadership Institute for Global Health Transformation, Saw Swee
Hock School of Public Health, National University of Singapore
*
November 15th 2022
* 11:45 am -12:30
Incentivising health: fostering value-based care
Jeremy Lim is director for global health in the Saw Swee Hock School of
Public Health, National University of Singapore, and leads the initiatives in
health systems strengthening and universal health coverage. He brings diverse
and unique perspectives, having spent substantial time in public and private
health care across Asia as well as in policy advisory with Singapore’s
Ministry of Health, the World Bank and the World Health Organisation. Outside
academia, he serves on the boards of various for-profit and not-for-profit
organisations in different aspects of health care, including migrant worker
health, end-of-life care and digital health interventions. He trained in
surgery and public health, attaining post-graduate qualifications in both the
UK and the US.
* View Profile
OLIVIA PANTELIDIS
Executive director, strategy and planning, Victorian Department of Health,
and executive director, Australian Centre for Value-Based Health Care
bar1 bar2
OLIVIA PANTELIDIS
Executive director, strategy and planning, Victorian Department of Health,
and executive director, Australian Centre for Value-Based Health Care
*
November 15th 2022
* 11:45 am -12:30
Incentivising health: fostering value-based care
* View Profile
SEEMANT JAUHARI
Managing partner, HealthXCapital
bar1 bar2
SEEMANT JAUHARI
Managing partner, HealthXCapital
*
November 15th 2022
* 11:45 am -12:30
Incentivising health: fostering value-based care
MODERATED BY
* View Profile
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
bar1 bar2
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
November 15th 2022
* 09:10 am -9:35
Ministerial keynote interview: a view from Indonesia
* 09:40 am -9:55
Spotlight interview
* 10:05 am -10:20
Exclusive keynote: Future of healthcare outlook
* 10:25 am -11:10
Panel: Removing silos—collaborating for success in health
* 11:45 am -12:30
Incentivising health: fostering value-based care
* 01:50 pm -2:35
Elevating access: financing health and universal healthcare
* 02:40 pm -3:05
Keynote interview
November 16th 2022
* 10:00 am -10:45
Balancing lives and livelihoods: preparedness for future pandemics in the
aftermath of covid-19
* 10:50 am -11:35
Jabs for the jab-nots: the future of open-source vaccines, mRNA and beyond
* 02:00 pm -2:45
Concurrent: The future of cancer care
David Humphreys is the global practice leader, health policy, Economist
Impact. He leads a multidisciplinary team that conducts high quality clinical
and policy analyses to inform micro level health decision making and produce
macro level perspectives. Supporting clients across the health ecosystem for
internal and external strategy making, David develops and directs engagements
on such issues as evidence-based reviews of new health technologies, future
healthcare challenges, value-based healthcare approaches for specific
therapeutic areas, and impact of new policy initiatives.
Previously, David held multiple roles at The EIU, first as the Americas
Director of Custom Research managing a business that delivered projects on
public policy and market strategy, and then as the Head of EIU Healthcare in
the US. Prior to joining The EIU, he was the senior director of Latin America
at Frost & Sullivan, where he led strategic analyses in industries such as
ICT and Healthcare, and spearheaded the firm’s expansion into the region. He
also served as a senior adviser at Management Partners, a consulting firm for
municipal governments in the US.
David holds an MBA degree and an honours certificate in international
business diplomacy from Georgetown University, and a BA in economics from
Ohio Wesleyan University. He has participated as a speaker at various
healthcare conferences, given lectures at academic institutions, led
strategic workshops and directed numerous expert panels with senior level
executives.
12:00 pm -1:30 SGT
PRIVATE ROUNDTABLE - FOSTERING RESILIENT ECONOMIES: PRIORITISING PANDEMIC
PREPAREDNESS
This roundtable seeks to convene healthcare leaders to determine the holistic
economic implications of the pandemic as well as investigate current policies
and reprioritise covid-19 as an ongoing concern that requires continuous
preparedness.
Apply to attend as a participant here.
MODERATED BY
* View Profile
ANDREW STAPLES
Regional head (APAC), policy and insights, Economist Impact
bar1 bar2
ANDREW STAPLES
Regional head (APAC), policy and insights, Economist Impact
November 15th 2022
* 12:00 pm -1:30
Private roundtable - Fostering resilient economies: prioritising pandemic
preparedness
Based in Singapore, Andrew Staples is the Asia-Pacific head of policy and
insights for Economist Impact. He leads a team across Asia, generating
evidence-based insights to inform internal strategy and external engagement
for governments, international institutions, corporations, foundations, and
NGOs around the world.
Andrew was previously global editorial director of The Economist Corporate
Network (ECN), the Economist group’s briefing and advisory service designed
to help senior business leaders understand and navigate the local and
regional business environment. He regularly chairs and moderates major
Economist events, delivers custom briefings to senior executives (including
Fortune 500 C-suite) and public figures (including heads of state) in his
areas of expertise which include international political economy, foreign
direct investment, international trade, corporate strategy and comparative
management. He also regularly appears in the international business media
(BBC, CNN, CNBC, Channel News Asia). Prior to his move to Singapore in 2016,
Andrew was the ECN director, North Asia, covering South Korea and Japan,
where he was a long-term resident.
Andrew has a PhD in International Political Economy and an MSc in East Asian
Business, both from the University of Sheffield, UK. He was a Ministry of
Education research scholar at Hitotsubashi University in Tokyo (2001-2003)
and before joining The Economist Group, Andrew pursued an academic career
holding both tenured and adjunct posts at leading universities and business
schools in Japan and the UK. He has published widely in his areas of
expertise and major publications include Responses to Regionalism in East
Asia: Japanese Production Networks in the Automotive Sector published as part
of the Palgrave Macmillan Asian Business Series and chapters in edited
volumes including Asian Inward and Outward FDI: New Challenges in the Global
Economy and popular textbooks including Asian Business and Management. Andrew
was also previously a Senior Editor for the internationally peer reviewed
journal Asian Business and Management.
12:30 pm -1:45 SGT
NETWORKING LUNCH
1:50 pm -2:35 SGT
ELEVATING ACCESS: FINANCING HEALTH AND UNIVERSAL HEALTHCARE
The plurality of Asia’s healthcare systems reflects the region’s diversity.
Developing countries often lack sufficient infrastructure and face significant
challenges in making healthcare accessible. Governments in Asia typically spend
only 4.5% of GDP on healthcare, but are nevertheless the dominant payer in the
region. Global healthcare spending growth will slow to 4.1% in 2022, despite
rising costs, as governments seek to repair budget deficits after the pandemic.
Outlays are trending upwards due to population ageing, rising demand for care,
advances in treatments and the expansion of public healthcare systems. The
pandemic has prodded governments to rethink their welfare provision. Against the
backdrop of rising inflation, how could a looming recession affect healthcare
and our priorities for spending? How will the future of healthcare be financed?
What can healthcare leaders do to prepare for the next crisis? Who will pay for
the future of healthcare? What are the implications for research and development
and innovation? What innovative financing models are available?
In 2015, at the United Nations (UN) Sustainable Development Summit, world
leaders committed to the goal of universal health coverage (UHC). But the future
sustainability of UHC is precarious. Most countries face a significant increase
in the burden of chronic and non-communicable diseases. Which regions are
leading in fostering UHC? Will we need to boost health literacy in Asia to
improve the accessibility of UHC and realise its full value? What policy changes
are needed to shore up UHC? Where can private health insurance schemes
supplement and complement publicly financed UHC initiatives?
* View Profile
ANIL ARGILLA
President, Emerging Markets Asia, Pfizer Inc
bar1 bar2
ANIL ARGILLA
President, Emerging Markets Asia, Pfizer Inc
November 15th 2022
* 01:50 pm -2:35
Elevating access: financing health and universal healthcare
Anil Argilla is the president, Emerging Markets Asia, for the global
biopharmaceuticals business at Pfizer. He is responsible for the entire
Pfizer business in Taiwan, Hong Kong, Thailand and Indochina (Laos, Cambodia,
Myanmar), Philippines, Indonesia, Malaysia and Brunei, Pakistan, Singapore
and Vietnam. He has handled a diverse range of roles, including cluster lead
Asia, regional commercial lead and country manager Indonesia. Prior to
joining Pfizer, Mr Argilla was with a management consulting firm focused on
organisational transformation and change. His consultancy experience provided
him with exposure to different industries, including automobile, IT/ ITES,
banking and petrochemicals.
Mr Argilla is a well-respected corporate executive and thought leader in the
pharmaceutical industry and a highly experienced professional whose career
spans across multiple industries. He is passionate about solving for equity
in health-care access and digital application in the life sciences industry.
He has worked and lived in India, China, Hong Kong and Indonesia and is
currently based in Singapore.
Mr Argilla is currently a board member of the US ASEAN Business Council. He
has a master’s degree in personnel management from Symbiosis Institute of
Business Management and a bachelor’s degree in commerce from Osmania
University.
* View Profile
LILY JIN
Emerging markets financing and author, “Inclusive Healthcare Investments in
Asia” report
bar1 bar2
LILY JIN
Emerging markets financing and author, “Inclusive Healthcare Investments in
Asia” report
*
November 15th 2022
* 01:50 pm -2:35
Elevating access: financing health and universal healthcare
Lily Jin authored the first of its kind investment report on healthcare
investments in Asia and organised an inaugural forum as a thought leader in
this space. Ms Jin currently also focuses on emerging markets financing.
Previously she was an international investment banker in New York City
serving the infrastructure and transportation sector.
Ms Jin also is the founder of HerValue, a women’s empowerment organisation
for finance and investments in China. She was selected as a fellow of the
Royal Society of Arts for driving social change in women’s empowerment in
finance in China.
* View Profile
SEJAL MISTRY
Regional director, South-east Asia, ACCESS Health International
bar1 bar2
SEJAL MISTRY
Regional director, South-east Asia, ACCESS Health International
November 15th 2022
* 01:50 pm -2:35
Elevating access: financing health and universal healthcare
Sejal Mistry leads the South-east Asia regional office of ACCESS Health to
lead and design initiatives and projects in innovative health financing,
digital technology and ageing. Ms Mistry has more than ten years’ experience
in international health policy, health financing and HIV/AIDS. Previously,
she worked with the South Korean Health Insurance Review and Assessment
Service and as a senior health policy and multilateral affairs adviser for
the US government with several agencies including the US State Department, US
Health and Human Services, and US National Institutes of Health.
MODERATED BY
* View Profile
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
bar1 bar2
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
November 15th 2022
* 09:10 am -9:35
Ministerial keynote interview: a view from Indonesia
* 09:40 am -9:55
Spotlight interview
* 10:05 am -10:20
Exclusive keynote: Future of healthcare outlook
* 10:25 am -11:10
Panel: Removing silos—collaborating for success in health
* 11:45 am -12:30
Incentivising health: fostering value-based care
* 01:50 pm -2:35
Elevating access: financing health and universal healthcare
* 02:40 pm -3:05
Keynote interview
November 16th 2022
* 10:00 am -10:45
Balancing lives and livelihoods: preparedness for future pandemics in the
aftermath of covid-19
* 10:50 am -11:35
Jabs for the jab-nots: the future of open-source vaccines, mRNA and beyond
* 02:00 pm -2:45
Concurrent: The future of cancer care
David Humphreys is the global practice leader, health policy, Economist
Impact. He leads a multidisciplinary team that conducts high quality clinical
and policy analyses to inform micro level health decision making and produce
macro level perspectives. Supporting clients across the health ecosystem for
internal and external strategy making, David develops and directs engagements
on such issues as evidence-based reviews of new health technologies, future
healthcare challenges, value-based healthcare approaches for specific
therapeutic areas, and impact of new policy initiatives.
Previously, David held multiple roles at The EIU, first as the Americas
Director of Custom Research managing a business that delivered projects on
public policy and market strategy, and then as the Head of EIU Healthcare in
the US. Prior to joining The EIU, he was the senior director of Latin America
at Frost & Sullivan, where he led strategic analyses in industries such as
ICT and Healthcare, and spearheaded the firm’s expansion into the region. He
also served as a senior adviser at Management Partners, a consulting firm for
municipal governments in the US.
David holds an MBA degree and an honours certificate in international
business diplomacy from Georgetown University, and a BA in economics from
Ohio Wesleyan University. He has participated as a speaker at various
healthcare conferences, given lectures at academic institutions, led
strategic workshops and directed numerous expert panels with senior level
executives.
2:40 pm -3:05 SGT
KEYNOTE INTERVIEW
* View Profile
MANUS POTAPORN
Deputy director general, Department of Medical Sciences, Ministry of Public
Health, Thailand
bar1 bar2
MANUS POTAPORN
Deputy director general, Department of Medical Sciences, Ministry of Public
Health, Thailand
November 15th 2022
* 02:40 pm -3:05
Keynote interview
MODERATED BY
* View Profile
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
bar1 bar2
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
November 15th 2022
* 09:10 am -9:35
Ministerial keynote interview: a view from Indonesia
* 09:40 am -9:55
Spotlight interview
* 10:05 am -10:20
Exclusive keynote: Future of healthcare outlook
* 10:25 am -11:10
Panel: Removing silos—collaborating for success in health
* 11:45 am -12:30
Incentivising health: fostering value-based care
* 01:50 pm -2:35
Elevating access: financing health and universal healthcare
* 02:40 pm -3:05
Keynote interview
November 16th 2022
* 10:00 am -10:45
Balancing lives and livelihoods: preparedness for future pandemics in the
aftermath of covid-19
* 10:50 am -11:35
Jabs for the jab-nots: the future of open-source vaccines, mRNA and beyond
* 02:00 pm -2:45
Concurrent: The future of cancer care
David Humphreys is the global practice leader, health policy, Economist
Impact. He leads a multidisciplinary team that conducts high quality clinical
and policy analyses to inform micro level health decision making and produce
macro level perspectives. Supporting clients across the health ecosystem for
internal and external strategy making, David develops and directs engagements
on such issues as evidence-based reviews of new health technologies, future
healthcare challenges, value-based healthcare approaches for specific
therapeutic areas, and impact of new policy initiatives.
Previously, David held multiple roles at The EIU, first as the Americas
Director of Custom Research managing a business that delivered projects on
public policy and market strategy, and then as the Head of EIU Healthcare in
the US. Prior to joining The EIU, he was the senior director of Latin America
at Frost & Sullivan, where he led strategic analyses in industries such as
ICT and Healthcare, and spearheaded the firm’s expansion into the region. He
also served as a senior adviser at Management Partners, a consulting firm for
municipal governments in the US.
David holds an MBA degree and an honours certificate in international
business diplomacy from Georgetown University, and a BA in economics from
Ohio Wesleyan University. He has participated as a speaker at various
healthcare conferences, given lectures at academic institutions, led
strategic workshops and directed numerous expert panels with senior level
executives.
3:10 pm -3:40 SGT
COFFEE BREAK
3:40 pm -4:25 SGT
SUPPLY CHAINS: FUTURE-PROOFING FOR RESILIENCE IN HEALTHCARE SYSTEMS
Covid-19 upended global supply chains across all sectors, highlighting the
vulnerabilities of centralised and highly integrated supply-chain networks.
Lockdowns this year in Shanghai and Shenzhen, cities accounting for more than
16% of China’s exports, raised alarm about supply chains once again. Bolstering
resilience is important because disruption is virtually guaranteed as a result
of climate change and shifts in trade policy or regulation, not to mention
cyber-attacks and the theft of intellectual property. Changing consumer spending
patterns have converged with long-term trends of increasing geopolitical
tension, digitisation and lean inventory strategies to put further pressure on
supply chains. Governments are keen to push ahead with regulation designed to
increase resilience and lower costs. Many countries are looking into reshoring
pharmaceutical production. How can forward-leaning organisations build more
resilient and nimble supply chains by shifting towards decentralisation? What
are the implications of “glocalisation” and onshoring for the future? Will
growing protectionism globally pose a threat to healthcare access in LMCs? As
the trade agenda looks to reignite after the covid-19 crisis, how will regional
integration affect healthcare supply chains? What are the limits and risks of
localising manufacturing for highly technical medical equipment?
* View Profile
ALEXANDER MAXWELL
Vice-president, healthcare supply chain operations, DKSH
bar1 bar2
ALEXANDER MAXWELL
Vice-president, healthcare supply chain operations, DKSH
November 15th 2022
* 03:40 pm -4:25
Supply chains: future-proofing for resilience in healthcare systems
* View Profile
FIDAH ALSAGOFF
Joint head of enterprise development group (Singapore) and head of life
sciences, Temasek
bar1 bar2
FIDAH ALSAGOFF
Joint head of enterprise development group (Singapore) and head of life
sciences, Temasek
November 15th 2022
* 03:40 pm -4:25
Supply chains: future-proofing for resilience in healthcare systems
* View Profile
JIADI YU
Chief investment officer, International Finance Corporation
bar1 bar2
JIADI YU
Chief investment officer, International Finance Corporation
*
November 15th 2022
* 03:40 pm -4:25
Supply chains: future-proofing for resilience in healthcare systems
Based in Hong Kong, Jiadi Yu leads IFC’s investments in health care and
education across Asia. She has supported the sustainable development and
widespread delivery of health care and education within the region since
2009. She previously engaged in equity investments and debt financing in
manufacturing and consumer services for Latin America, eastern Europe and
Africa from IFC’s headquarters in Washington, DC.
Prior to IFC, Ms Yu worked in the capital markets department at the World
Bank in Washington, DC, and at the Shanghai Asset and Equity Exchange. She
holds a master’s degree in public policy from Harvard University and a
bachelor of arts degree from Renmin University of China. IFC, a member of the
World Bank Group, is the world’s largest multilateral investor in private
health care and education.
IFC works to increase access to high-quality health and education by making
direct investments, sharing industry knowledge and expertise, funding smaller
companies, raising medical and education standards, and helping clients
expand services to lower-income groups.
* View Profile
PRIVATE: KANGHO LEE
Deputy minister, Global Vaccine Hub Office, Ministry of Health and Welfare,
South Korea
bar1 bar2
PRIVATE: KANGHO LEE
Deputy minister, Global Vaccine Hub Office, Ministry of Health and Welfare,
South Korea
November 15th 2022
* 03:40 pm -4:25
Supply chains: future-proofing for resilience in healthcare systems
Kangho Lee has worked for 29 years in the South Korean government and has
managed several policy areas such as covid-19 vaccine and therapeutics
policies, bio-workforce training, population policy, social service policy,
international relations and budget management. Mr Lee is currently deputy
minister of the Global Vaccine Hub Office of the Ministry of Health and
Welfare (MOHW). He has served as director-general of the Health Industry
Bureau, where he developed bio-health industry programmes as well as
pharmaceuticals and vaccines. He also served as director-general of the
Social Service Policy Bureau at the MOHW, where he managed programmes such as
care services for the aged and the disabled.
Mr Lee is co-chair of the executive committee of the Global Biomanufacturing
Workforce Training Hub, which is dedicated to empowering low- and
middle-income countries with self-sufficient vaccine production capacity by
providing training for manufacturing. He had launched and served as the
co-chair of the steering committee of the Public Expenditure Management
Network in Asia (PEMNA) for two and half years. He also initiated the PEMNA
secretariat in Seoul.
Mr Lee earned a PhD in public administration and a BA in economics from Seoul
National University, and an MA in public administration from the Kennedy
School of Government at Harvard University.
MODERATED BY
* View Profile
NURIESYA SALEHA
Senior manager, health practice, Economist Impact
bar1 bar2
NURIESYA SALEHA
Senior manager, health practice, Economist Impact
November 15th 2022
* 03:40 pm -4:25
Supply chains: future-proofing for resilience in healthcare systems
November 16th 2022
* 12:05 pm -12:50
Antimicrobial resistance: the overlooked pandemic and its implications for
preventive care
Nuriesya Saleha is the senior manager of the health practice team for
Asia-Pacific at Economist Impact. She is a part of the policy and insights
team based in Singapore, working with multi-disciplinary teams across the
globe on projects spanning a range of disease focus areas. Ms Saleha has been
in the healthcare sector for nearly ten years. She previously worked at
Woodlands Health, an upcoming public healthcare campus in Singapore,
developing new clinical models and processes by engaging with various
clinical stakeholders. Prior to that, she was involved in
managed-care-related projects in Singapore and Malaysia at Fullerton Health,
and did health system operations and research at Johns Hopkins in Baltimore.
She has a master’s degree in health administration from Johns Hopkins
University and undergraduate degree in economics and biochemistry.
4:30 pm -5:10 SGT
ENABLING THE PATIENT VOICE
Patient empowerment is important to ensure that patient voices are valued and
treatment plans are adhered to. Increased health literacy helps patients become
more aware of decisions regarding their health, driving care continuity. The
benefits extend beyond the clinical setting into the patient’s community. In
some low- and middle-income countries (LMCs), though, governments see patient
groups as activists. Can patient empowerment drive more equitable healthcare
systems in the region? How can we move from confrontation to collaboration in
these countries? How can we value individual needs and preferences in the
patient journey?
Empowerment also means that patients should be comfortable sharing their
concerns with physicians. Europe and the United States have formalised measures
to increase patient engagement in their regulation and reimbursement systems.
Patient-specific guidelines that support learning already exist such as courses
from the Global Allergy & Airways Patient Platform (GAAPP). Further effort is
needed to translate guidelines from scientific into non-technical language so
they are more accessible to patients. How can patient flows and health systems
be structured to allow enough time for healthcare professionals (HCPs) to
connect with their patients? In Asia and beyond, where can key stakeholders
build patients’ capacity to contribute to processes around regulation and
reimbursement decision-making in a meaningful and informed way? What part does
fostering health literacy play in all this? What cultural sensitivities need to
be considered in the region in this context?
* View Profile
AI LING SIM-DEVADAS
Co-chair, SingHealth Patient Advocacy Network
bar1 bar2
AI LING SIM-DEVADAS
Co-chair, SingHealth Patient Advocacy Network
*
*
November 15th 2022
* 04:30 pm -5:10
Enabling the patient voice
Ai Ling Sim-Devadas is the co-chair of the SingHealth Patient Advocacy
Network (SPAN) and is a cancer survivor. She is passionate about what
patients and families can do to make health care better, safer, and more
patient and family centred.
Ms Sim-Devadas has been shaping the role of SPAN in the health-care system by
bringing the voices of patients and families to the heart of health care to
improve patient experience. To enable patient engagement in health-care
improvement projects, she has worked with health-care teams to drive training
programmes for patient advocates as well as develop a patient engagement
guide for health-care professionals.
With a strong professional background in health-care communications, patient
experience and volunteer management, Ms Sim-Devadas brings valuable
perspectives from both ends of the care spectrum—that of a health-care
provider and a patient. She is a certified patient experience professional
(CPXP).
Ms Sim-Devadas also serves on the Beryl Institute Global Patient and Family
Advisory Board. Besides patient advocacy she also volunteers with palliative
care charities. She is a board member for Ambulance Wish Singapore, a charity
for fulfilling last wishes for terminally ill patients.
* View Profile
ANN SINGLE
Advisory committee member, Patient Voice Initiative
bar1 bar2
ANN SINGLE
Advisory committee member, Patient Voice Initiative
*
November 15th 2022
* 04:30 pm -5:10
Enabling the patient voice
* View Profile
EINSTEIN ROJAS
Board member, Philippine Alliance of Patient Organisations
bar1 bar2
EINSTEIN ROJAS
Board member, Philippine Alliance of Patient Organisations
November 15th 2022
* 04:30 pm -5:10
Enabling the patient voice
Einstein Rojas is a board member of the Philippine Alliance of Patient
Organisations. Mr Rojas is also an innovation consultant and an engagement
manager of Embiggen Group, based in the US and the Philippines.
He is a certified innovation professional by the Global Innovation Management
Institute, Cambridge, Massachusetts. He holds a master of science in
innovation and business from the Asian Institute of Management and is a
recognised innovation coach for college students at the Far Eastern
University Institute of Technology Innovation Centre.
MODERATED BY
* View Profile
EMILY TIEMANN
Manager, health practice, Economist Impact
bar1 bar2
EMILY TIEMANN
Manager, health practice, Economist Impact
November 15th 2022
* 08:00 am -9:00
Private roundtable - Personalised healthcare at scale: technology lessons
for equity post-pandemic
* 04:30 pm -5:10
Enabling the patient voice
November 16th 2022
* 12:05 pm -12:50
Concurrent: Women’s health: building a roadmap for equity
* 02:50 pm -3:35
Healthspan over lifespan: mitigating the diseases of ageing
Emily Tiemann is a Health Practice Manager in the Policy and Insights team at
Economist Impact in Singapore, where she is involved in projects ranging from
Breast Cancer, Fertility and Digital Health. Prior to this, she worked in
policy at the HFEA, the UK’s fertility regulator, leading projects related to
consent, the Code of Practice and clinic inspections. She also worked closely
with the Department of Health to outline the new upcoming legislation related
to extending the storage periods of gametes and embryos beyond 10 years.
Emily started her career as an embryologist at fertility clinics carrying out
diagnostic and micromanipulation procedures. Emily has a degree in Biology
from McGill University in Canada and a Master’s degree in Women’s Health from
University College London.
5:15 pm -6:00 SGT
DEI IN THE DNA: IMPROVING DIVERSITY, EQUITY AND INCLUSION IN HEALTHCARE
As the covid-19 crisis recedes, governments across the world are emphasising the
need to “build back better” with a renewed focus on addressing existing
inequalities. This post-pandemic recovery will take positive action in all
domains of environmental, social and corporate governance (ESG). Certain
communities and groups face barriers to accessing healthcare, whether due to
ethnicity, disability, gender or income. Many devices and treatments work less
well for non-white people and women. Pulse oximeters, for example, overestimate
blood-oxygen saturation more frequently in black people than white. Medical
technology should be designed from the outset to be free from such bias.
Generally speaking, it is designed by white men and tested on white men. This
fact has potentially lethal consequences for many in society. Stakeholders today
expect businesses to deliver positive social outcomes alongside financial
returns, demanding more diversity and inclusion. Employee variety has been
linked to innovation, productivity and, for example in diverse teams of
surgeons, fewer mistakes. Where are we on diversity, equity and inclusion (DEI)
in healthcare? To what extent is DEI a de-risking strategy? How can healthcare
leaders build DEI into their DNA? How can we ensure patient data is
representative and build that representation at every point in the healthcare
value chain? How can we engage underserved and indigenous populations to
increase their participation in clinical trials, regular health screenings and
beyond? Where are problems of insufficient diversity and inclusion most acute?
* View Profile
DEBORAH SEIFERT
Country manager, Thailand and Indochina, Pfizer Inc, and Chairperson, Pfizer
Emerging Markets Asia Regional Council on Diversity, Equity and Inclusion
bar1 bar2
DEBORAH SEIFERT
Country manager, Thailand and Indochina, Pfizer Inc, and Chairperson, Pfizer
Emerging Markets Asia Regional Council on Diversity, Equity and Inclusion
November 15th 2022
* 05:15 pm -6:00
DEI in the DNA: improving diversity, equity and inclusion in healthcare
Deborah Seifert was appointed country manager of Pfizer Thailand and
Indochina markets (Myanmar, Cambodia and Laos) in April 2020 to oversee
Pfizer Biopharmaceutical Group operations in Thailand and Indochina. In her
role, she leads Pfizer in its purpose of bringing breakthroughs that change
patients’ lives. Her focus is on driving access to innovative medicines by
both exercising internal co-ordination and engaging external top-level
representatives to lead the conversation and drive positive change for public
health in the country. She also serves as the chairperson of the Emerging
Markets Asia Regional Council on Diversity, Equity and Inclusion.
Ms Seifert joined Wyeth in 1993 as part of its in-house advertising agency
for Pfizer, where she worked on multiple products and ultimately joined the
marketing team in the women’s health-care business unit in the US in 2001.
Following the acquisition of Wyeth by Pfizer in 2009, she was transferred to
Pfizer. During her more than 25 years with Wyeth and Pfizer, she has held
various management positions, including commercial operations, marketing and
commercial development. Prior to leading the Thailand and Indochina market,
Ms Seifert was Pfizer Emerging Markets group lead of inflammation and
immunology, based in New York.
Ms Seifert serves on the board of governors of the American Chamber of
Commerce in Thailand. She holds a bachelor’s degree in economics from
Bucknell University.
* View Profile
JENNIFER BUCKLEY
Founder and managing director, Sweef Capital
bar1 bar2
JENNIFER BUCKLEY
Founder and managing director, Sweef Capital
*
November 15th 2022
* 05:15 pm -6:00
DEI in the DNA: improving diversity, equity and inclusion in healthcare
* View Profile
VIVEK TOMAR
Co-founder, Rise To Survive Cancer
bar1 bar2
VIVEK TOMAR
Co-founder, Rise To Survive Cancer
*
*
November 15th 2022
* 05:15 pm -6:00
DEI in the DNA: improving diversity, equity and inclusion in healthcare
MODERATED BY
* View Profile
CHEE HEW
Director, data analytics and consulting, Clearstate, EIU Healthcare
bar1 bar2
CHEE HEW
Director, data analytics and consulting, Clearstate, EIU Healthcare
November 15th 2022
* 05:15 pm -6:00
DEI in the DNA: improving diversity, equity and inclusion in healthcare
November 17th 2022
* 12:05 pm -12:50
Data and interoperability in healthcare: ethics, opportunities and the way
forward
Chee is an experienced consultant in the healthcare and life sciences sector
in North America and Asia Pacific, with more than 18 years of experience in
business and operational strategy consulting, leveraging strong market
research capabilities. She has more than 12 years of healthcare experience
specifically in China.
Prior to joining EIU Healthcare, Chee was the Strategy & Change
Pharmaceutical leader in IBM Global Business Services (previously
PricewaterhouseCoopers) in China. Before that, she was with the North
American R&D pharmaceutical industry practice based in Toronto.
Chee has extensive experience working with senior executives of both
healthcare and life sciences companies and government organizations to
develop and implement strategic plans.
Chee focuses on med tech globally, working with global IVD leaders such as
Abbott Diagnostics, Roche Diagnostics, Danaher (i.e. Beckman Coulter, Leica,
Radiometer), Bio-Rad and Sysmex. Chee has managed large scale projects to
provide credible market insights to help clients achieve sustainable growth.
In Asia Pacific, she has worked with other medical technology companies and
research institutes. She has led numerous consulting projects to formulate
winning go-to-market strategies in emerging markets in Asia Pacific and Latin
America.
She has published various white papers and presented at major conferences on
current healthcare topics in Asia. She has covered topics such as “Future
Outlook for Health in China”, “SE Asia: The New Emerging Healthcare Market
Challenge”, “Digital Healthcare”, etc.
Chee holds an MBA from Schulich School of Business, York University (Canada)
and BSc (Hons) in Microbiology from University of Toronto.
* Full Day
* Plenary
* Pandemics & integrated care
* Preventive systems & NCDs
Plenary Pandemics & integrated care Preventive systems & NCDs
9:00 am -10:00 SGT
REGISTRATION AND COFFEE
10:00 am -10:45 SGT
CONCURRENT: DRIVING ACCESS AND PREVENTION: DIGITAL DIAGNOSTICS AND THERAPEUTICS
Rising wealth and healthcare demands are driving an appetite for medtech in the
region. Digitisation spurred on by the covid-19 crisis has ushered in an
acceptance of remote medical products and services, and alternative care models.
Technological innovation can boost progress across the UN SDG agenda, if
supported by regulation to facilitate access. In some countries, the hospital
can even come to the patient. Hospitals as we know them might play an
increasingly smaller role in the future driving a need to integrate digital
devices and home care to make care available everywhere. Wearable devices could
transform the future of health care. Soon, wearables could unobtrusively measure
people’s blood sugar and alcohol concentration, hydration, markers of liver and
kidney function and lots more. Where are we on digital diagnostics and
therapeutics? Where are we on wearables? How can digital diagnostics open up
access to experts for rural or remote patients? Is AI ready to make
life-changing decisions in remote diagnostics? Will emerging technology replace
workers in healthcare or simply augment the workflow of existing HCPs? Should
money be spent on new technologies when resources are scarce? How do we mitigate
biases in digital devices such as oximeters? How do we incentivise focus on
preventive health when curative health has historically been more incentivised?
* View Profile
BENEDICT TAN
Group chief digital strategy officer and chief data officer, Singapore Health
Services (SingHealth)
bar1 bar2
BENEDICT TAN
Group chief digital strategy officer and chief data officer, Singapore Health
Services (SingHealth)
November 16th 2022
* 10:00 am -10:45
Concurrent: Driving access and prevention: digital diagnostics and
therapeutics
* View Profile
MICHAEL HO
Head of innovation and strategy, National Health Innovation Centre, Singapore
bar1 bar2
MICHAEL HO
Head of innovation and strategy, National Health Innovation Centre, Singapore
*
November 16th 2022
* 10:00 am -10:45
Concurrent: Driving access and prevention: digital diagnostics and
therapeutics
* View Profile
SIDNEY YEE
Founding chief executive, Diagnostics Development Hub (DxD Hub) and Advisor,
Innovation and Enterprise division, A*STAR
bar1 bar2
SIDNEY YEE
Founding chief executive, Diagnostics Development Hub (DxD Hub) and Advisor,
Innovation and Enterprise division, A*STAR
November 16th 2022
* 10:00 am -10:45
Concurrent: Driving access and prevention: digital diagnostics and
therapeutics
* View Profile
SWEE KHENG KHOR
Chief executive, Angsana Health
bar1 bar2
SWEE KHENG KHOR
Chief executive, Angsana Health
*
*
*
November 16th 2022
* 10:00 am -10:45
Concurrent: Driving access and prevention: digital diagnostics and
therapeutics
MODERATED BY
* View Profile
SOOK CHEN LEE
Senior principal consultant, Clearstate, EIU Healthcare
bar1 bar2
SOOK CHEN LEE
Senior principal consultant, Clearstate, EIU Healthcare
November 16th 2022
* 10:00 am -10:45
Concurrent: Driving access and prevention: digital diagnostics and
therapeutics
Sook Chen is a Senior Principal at Clearstate, the Economist’s healthcare
consulting arm. She has over 12 years of experience in healthcare consulting,
leveraging strong market intelligence and analytics capabilities to uncover
market insights and provide actionable strategies. Her experience spans
across the healthcare ecosystem, covering diagnostics, medical devices, life
sciences, therapeutics & pharmaceuticals.
Sook Chen has extensive experience working with prominent healthcare
companies such as J&J, Abbott, Baxter, Roche, Danaher, Pfizer and Philips.
Coupled with her strong background in Asia Pacific’s healthcare ecosystem and
its unique challenges, Sook Chen is able to provide credible insights to both
commercial and strategic leaders within these organisations.
Prior to joining EIU Healthcare, Sook Chen was a seasoned strategy and
business consultant at Deloitte Consulting (SEA) for over 6 years. Sook Chen
holds a Bachelor of Science in Economics from University of York.
10:00 am -10:45 SGT
BALANCING LIVES AND LIVELIHOODS: PREPAREDNESS FOR FUTURE PANDEMICS IN THE
AFTERMATH OF COVID-19
Billions of doses of vaccine have been administered, new therapeutics are on
their way and, in many countries, life seems to be opening up. But covid-19 is
here to stay. Countries with solid public-health infrastructure and good access
to healthcare and vaccines are likely to be more resilient in coming phases. In
the most optimistic scenario, covid-19 infections will flare up periodically,
especially during winter or when new variants emerge. America and Britain are
examples of countries that have decided to learn to live with the virus. China
has taken a different course, and over the past two years it has had a lower
mortality rate from covid-19 and stronger economic growth than any other big
country. But each new case is testing the government’s “zero-covid” strategy,
which uses mass testing and lockdowns to crush any hint of an outbreak. A study
published last year out of China found that during an early lockdown, deaths
from chronic illnesses exceeded expected rates by 21%. Many people in China have
little or no immunity to covid-19, and immunologically naive populations pose a
huge risk for the rest of the world. New variants are likely to emerge from
these groups. In the worst-case scenario, a deadly new vaccine-resistant variant
could set the world’s pandemic clock back to zero.
How are we keeping solutions catalysed by covid-19, such as contact tracing,
alive for the next pandemic? How can we maintain the infrastructure, and who
will pay for it? How can continuity in preparedness be established? Hong Kong
once boasted a very low case count. But Omicron overwhelmed the city in March.
Most of the dead have been unvaccinated old folk. Despite having more cases at a
similar time, South Korea’s stronger vaccine roll-out led to less deaths. How
can healthcare leaders strike a balance between preventing resurgences of the
virus and protecting the economy? What lessons has the world learned? What will
normality look like in the next two years? Where will the next variant come
from? How are we dealing with long covid? What is being done to ensure
preparedness and resilience for the inevitable next pandemic? Who will pay for
this future-proofing? What is the status of the WHO’s global treaty to codify
the global response to pandemics?
* View Profile
ANITA SURESH
Deputy director of genomics and sequencing, FIND
bar1 bar2
ANITA SURESH
Deputy director of genomics and sequencing, FIND
*
*
November 16th 2022
* 10:00 am -10:45
Balancing lives and livelihoods: preparedness for future pandemics in the
aftermath of covid-19
* View Profile
CHEONG WEI YANG
Deputy secretary (technology), Ministry of Health, Singapore
bar1 bar2
CHEONG WEI YANG
Deputy secretary (technology), Ministry of Health, Singapore
*
November 16th 2022
* 10:00 am -10:45
Balancing lives and livelihoods: preparedness for future pandemics in the
aftermath of covid-19
* View Profile
SHAWN VASOO
Clinical director, National Centre for Infectious Diseases, Singapore
bar1 bar2
SHAWN VASOO
Clinical director, National Centre for Infectious Diseases, Singapore
*
November 16th 2022
* 10:00 am -10:45
Balancing lives and livelihoods: preparedness for future pandemics in the
aftermath of covid-19
* View Profile
ANIRUDDHA PATIL
Unit head, health and education investments, Asian Development Bank
bar1 bar2
ANIRUDDHA PATIL
Unit head, health and education investments, Asian Development Bank
*
November 16th 2022
* 10:00 am -10:45
Balancing lives and livelihoods: preparedness for future pandemics in the
aftermath of covid-19
MODERATED BY
* View Profile
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
bar1 bar2
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
November 15th 2022
* 09:10 am -9:35
Ministerial keynote interview: a view from Indonesia
* 09:40 am -9:55
Spotlight interview
* 10:05 am -10:20
Exclusive keynote: Future of healthcare outlook
* 10:25 am -11:10
Panel: Removing silos—collaborating for success in health
* 11:45 am -12:30
Incentivising health: fostering value-based care
* 01:50 pm -2:35
Elevating access: financing health and universal healthcare
* 02:40 pm -3:05
Keynote interview
November 16th 2022
* 10:00 am -10:45
Balancing lives and livelihoods: preparedness for future pandemics in the
aftermath of covid-19
* 10:50 am -11:35
Jabs for the jab-nots: the future of open-source vaccines, mRNA and beyond
* 02:00 pm -2:45
Concurrent: The future of cancer care
David Humphreys is the global practice leader, health policy, Economist
Impact. He leads a multidisciplinary team that conducts high quality clinical
and policy analyses to inform micro level health decision making and produce
macro level perspectives. Supporting clients across the health ecosystem for
internal and external strategy making, David develops and directs engagements
on such issues as evidence-based reviews of new health technologies, future
healthcare challenges, value-based healthcare approaches for specific
therapeutic areas, and impact of new policy initiatives.
Previously, David held multiple roles at The EIU, first as the Americas
Director of Custom Research managing a business that delivered projects on
public policy and market strategy, and then as the Head of EIU Healthcare in
the US. Prior to joining The EIU, he was the senior director of Latin America
at Frost & Sullivan, where he led strategic analyses in industries such as
ICT and Healthcare, and spearheaded the firm’s expansion into the region. He
also served as a senior adviser at Management Partners, a consulting firm for
municipal governments in the US.
David holds an MBA degree and an honours certificate in international
business diplomacy from Georgetown University, and a BA in economics from
Ohio Wesleyan University. He has participated as a speaker at various
healthcare conferences, given lectures at academic institutions, led
strategic workshops and directed numerous expert panels with senior level
executives.
10:50 am -11:35 SGT
JABS FOR THE JAB-NOTS: THE FUTURE OF OPEN-SOURCE VACCINES, MRNA AND BEYOND
Ramping up local capacity to make vaccines should be the cornerstone of a more
resilient public-health infrastructure. Over the past year many leaders in
Africa and other developing regions have watched vast disparities open up in the
share of populations that have been fully vaccinated against covid-19. A year of
rampant vaccine nationalism left the 1.2 billion people in 54 African countries
at the back of the queue. The plight of the “jab-nots” in the developing world
has rallied some to embrace “open-source” pharma and vaccines, whose potential
remains to be seen. The WHO has set up a technology transfer hub in South
Africa, where it hopes scientists will learn how to make mRNA vaccines and
spread that knowledge across the continent. Decades of research helped set the
stage for humanity to maximise the potential and power of Ramping up local
capacity to make vaccines should be the cornerstone of a more resilient
public-health infrastructure. Over the past year many leaders in Africa and
other developing regions have watched vast disparities open up in the share of
populations that have been fully vaccinated against covid-19. A year of rampant
vaccine nationalism left the 1.2 billion people in 54 African countries at the
back of the queue. The plight of the “jab-nots” in the developing world has
rallied some to embrace “open-source” pharma and vaccines, whose potential
remains to be seen. The WHO has set up a technology transfer hub in South
Africa, where it hopes scientists will learn how to make mRNA vaccines and
spread that knowledge across the continent. Decades of research helped set the
stage for humanity to maximise the potential and power of mRNA when we needed it
to address covid-19. The goal is now to build nimble vaccine supply chains that
are ready to start producing as soon as the genetic sequence of a virus or
variant is mapped. This panel seeks to explore the future of vaccines, including
mRNA and open-source vaccines, and how they can deliver access to better health
for all. How can healthcare leaders close the gap between the jabs and jab-nots
in the future?
* View Profile
CLAUDIA NANNEI
Senior technical officer, World Health Organisation
bar1 bar2
CLAUDIA NANNEI
Senior technical officer, World Health Organisation
November 16th 2022
* 10:50 am -11:35
Jabs for the jab-nots: the future of open-source vaccines, mRNA and beyond
* View Profile
HARISH IYER
Deputy director, digital and health innovations, Bill & Melinda Gates
Foundation
bar1 bar2
HARISH IYER
Deputy director, digital and health innovations, Bill & Melinda Gates
Foundation
November 16th 2022
* 10:50 am -11:35
Jabs for the jab-nots: the future of open-source vaccines, mRNA and beyond
* View Profile
PAUL PRONYK
Director, Duke-NUS Centre for Outbreak Preparedness
bar1 bar2
PAUL PRONYK
Director, Duke-NUS Centre for Outbreak Preparedness
*
November 16th 2022
* 10:50 am -11:35
Jabs for the jab-nots: the future of open-source vaccines, mRNA and beyond
* View Profile
PETER HOTEZ
Dean, National School of Tropical Medicine, Baylor College of Medicine
bar1 bar2
PETER HOTEZ
Dean, National School of Tropical Medicine, Baylor College of Medicine
*
November 16th 2022
* 10:50 am -11:35
Jabs for the jab-nots: the future of open-source vaccines, mRNA and beyond
Peter J Hotez is an internationally recognised physician-scientist in
neglected tropical diseases and vaccine development. He is dean of the
National School of Tropical Medicine and professor of paediatrics and
molecular virology and microbiology at Baylor College of Medicine, where he
is also the co-director of the Texas Children’s Centre for Vaccine
Development and endowed chair of tropical paediatrics at Texas Children’s
Hospital. He is also university professor at Baylor University, fellow in
disease and poverty at the James A Baker III Institute for Public Policy,
senior fellow at the Scowcroft Institute of International Affairs at Texas
A&M University, faculty fellow with the Hagler Institute for Advanced Study
at Texas A&M University and health policy scholar in the Baylor Centre for
Medical Ethics and Health Policy.
Dr Hotez served previously as president of the American Society of Tropical
Medicine and Hygiene and he is founding editor-in-chief of PLoS Neglected
Tropical Diseases. He is an elected member of the National Academy of
Medicine (public health section) and the American Academy of Arts and
Sciences (public policy section). In 2014–16, he served in the Obama
administration as US envoy, focusing on vaccine diplomacy initiatives between
the US government and countries in the Middle East and North Africa. In 2022
Dr Hotez and his colleague Dr Maria Elena Bottazzi were nominated for the
Nobel Peace Prize for their efforts to develop and distribute a low-cost
covid-19 vaccine.
MODERATED BY
* View Profile
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
bar1 bar2
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
November 15th 2022
* 09:10 am -9:35
Ministerial keynote interview: a view from Indonesia
* 09:40 am -9:55
Spotlight interview
* 10:05 am -10:20
Exclusive keynote: Future of healthcare outlook
* 10:25 am -11:10
Panel: Removing silos—collaborating for success in health
* 11:45 am -12:30
Incentivising health: fostering value-based care
* 01:50 pm -2:35
Elevating access: financing health and universal healthcare
* 02:40 pm -3:05
Keynote interview
November 16th 2022
* 10:00 am -10:45
Balancing lives and livelihoods: preparedness for future pandemics in the
aftermath of covid-19
* 10:50 am -11:35
Jabs for the jab-nots: the future of open-source vaccines, mRNA and beyond
* 02:00 pm -2:45
Concurrent: The future of cancer care
David Humphreys is the global practice leader, health policy, Economist
Impact. He leads a multidisciplinary team that conducts high quality clinical
and policy analyses to inform micro level health decision making and produce
macro level perspectives. Supporting clients across the health ecosystem for
internal and external strategy making, David develops and directs engagements
on such issues as evidence-based reviews of new health technologies, future
healthcare challenges, value-based healthcare approaches for specific
therapeutic areas, and impact of new policy initiatives.
Previously, David held multiple roles at The EIU, first as the Americas
Director of Custom Research managing a business that delivered projects on
public policy and market strategy, and then as the Head of EIU Healthcare in
the US. Prior to joining The EIU, he was the senior director of Latin America
at Frost & Sullivan, where he led strategic analyses in industries such as
ICT and Healthcare, and spearheaded the firm’s expansion into the region. He
also served as a senior adviser at Management Partners, a consulting firm for
municipal governments in the US.
David holds an MBA degree and an honours certificate in international
business diplomacy from Georgetown University, and a BA in economics from
Ohio Wesleyan University. He has participated as a speaker at various
healthcare conferences, given lectures at academic institutions, led
strategic workshops and directed numerous expert panels with senior level
executives.
10:50 am -11:35 SGT
CONCURRENT: HEADHUNTING FOR HEALTH: ALLEVIATING THE LABOUR SHORTAGE
The ratio of doctors per thousand patients in Asia is less than the OECD
average, and the world is short 9m nurses according to WHO estimates. Some of
the countries worst affected by this labour shortage are in Asia. Covid-19 has
also killed between 80,000 and 180,000 healthcare workers worldwide, according
to the WHO. Clinics and hospitals around the globe are struggling to recruit and
retain staff, and the pharmacy industry is facing a similar problem. Where did
all the workers go? Falling birth rates, family care needs during the pandemic
and record numbers of people leaving the workforce altogether make it harder to
recruit staff in all sectors. Unfilled vacancies, at 30m across the rich world
across multiple sectors, have never been so high. Countries like Australia, with
borders shut in response to the global pandemic, are facing a massive skills
shortage. Without proper workforce planning, efforts to catch up on a backlog of
non-covid care will fail. Healthcare providers and professionals also struggle
to stay up to date with the constant deluge of new medical studies and data. How
can healthcare organisations mitigate the labour shortage to ensure continuity
of care? What upskilling or knowledge infrastructure should healthcare leaders
consider to retain talent and optimise their workforce? What role will the
metaverse play in optimising tomorrow’s healthcare workforce?
* View Profile
DOREEN SU-YIN TAN
Associate professor, National University of Singapore and Cardiology
specialist pharmacist, National University Heart Centre, Singapore
bar1 bar2
DOREEN SU-YIN TAN
Associate professor, National University of Singapore and Cardiology
specialist pharmacist, National University Heart Centre, Singapore
*
*
November 16th 2022
* 10:50 am -11:35
Concurrent: Headhunting for health: alleviating the labour shortage
* View Profile
LLUIS VINALS TORRES
Coordinator, health policy and services design, World Health Organisation,
Western Pacific Region
bar1 bar2
LLUIS VINALS TORRES
Coordinator, health policy and services design, World Health Organisation,
Western Pacific Region
November 16th 2022
* 10:50 am -11:35
Concurrent: Headhunting for health: alleviating the labour shortage
* View Profile
MARGARETA LAMINTO
Group chief commercial officer and group chief sustainability officer,
Fullerton Health
bar1 bar2
MARGARETA LAMINTO
Group chief commercial officer and group chief sustainability officer,
Fullerton Health
November 16th 2022
* 10:50 am -11:35
Concurrent: Headhunting for health: alleviating the labour shortage
MODERATED BY
* View Profile
RITU BHANDARI
Manager, policy and insights, Economist Impact
bar1 bar2
RITU BHANDARI
Manager, policy and insights, Economist Impact
November 16th 2022
* 10:50 am -11:35
Concurrent: Headhunting for health: alleviating the labour shortage
Ritu Bhandari is a manager with the Policy and Insights team at Economist
Impact. She has over seven years of experience working in a wide range of
public policy topics including food security, technology and sustainability.
At Economist Impact, she manages research programs for private-sector,
governments and NGO clients in Asia, covering topics like agriculture and
food, climate and sustainability, and technology. She holds a Master’s degree
in Public Policy from Lee Kuan Yew School of Public Policy, National
University of Singapore, where she specialised in economic policy analysis.
11:35 am -12:00
COFFEE BREAK
12:05 pm -12:50 SGT
CONCURRENT: WOMEN’S HEALTH: BUILDING A ROADMAP FOR EQUITY
Around the globe healthcare systems seem to have failed women in many ways.
Constrained choices and lack of access to appropriate and timely care contribute
to gender disparities in outcomes, particularly in areas like oncology. Men are
often the subject of studies. As a result, plenty of health issues specific to
women have, despite their ubiquity, been routinely neglected. Women are also
often at a disadvantage in treatment. Procedures such as hip implants and heart
surgery, for example, are more likely to fail in them than in men. Of the
world’s regions, East Asia experiences the greatest numbers of female cancer
cases and deaths. Addressing the cancer burden in women recognises opportunities
to tackle gender inequities that have long plagued women’s health more widely.
Which disease trends in women require our most urgent attention? How could
patient pathways in various social groups be improved to ensure equal access to
healthcare? What system needs to be put in place to translate the aim of
healthcare equity into practical steps that deliver more inclusive care and
support? How much investment is needed to reach targets, and where will these
resources come from? This session will look at systemic issues in women’s health
and how they highlight global disparities in healthcare access.
* View Profile
HSIEN-HSIEN LEI
Chief executive, American Chamber of Commerce (AmCham), Singapore and Adjunct
associate professor, Saw Swee Hock School of Public Health, National
University of Singapore
bar1 bar2
HSIEN-HSIEN LEI
Chief executive, American Chamber of Commerce (AmCham), Singapore and Adjunct
associate professor, Saw Swee Hock School of Public Health, National
University of Singapore
*
November 16th 2022
* 12:05 pm -12:50
Concurrent: Women’s health: building a roadmap for equity
* View Profile
RITU JAIN
President, DEBRA International
bar1 bar2
RITU JAIN
President, DEBRA International
*
*
*
November 16th 2022
* 12:05 pm -12:50
Concurrent: Women’s health: building a roadmap for equity
* View Profile
YOLANDA AUGUSTIN
Oncologist, St George's University of London
bar1 bar2
YOLANDA AUGUSTIN
Oncologist, St George's University of London
November 16th 2022
* 12:05 pm -12:50
Concurrent: Women’s health: building a roadmap for equity
MODERATED BY
* View Profile
EMILY TIEMANN
Manager, health practice, Economist Impact
bar1 bar2
EMILY TIEMANN
Manager, health practice, Economist Impact
November 15th 2022
* 08:00 am -9:00
Private roundtable - Personalised healthcare at scale: technology lessons
for equity post-pandemic
* 04:30 pm -5:10
Enabling the patient voice
November 16th 2022
* 12:05 pm -12:50
Concurrent: Women’s health: building a roadmap for equity
* 02:50 pm -3:35
Healthspan over lifespan: mitigating the diseases of ageing
Emily Tiemann is a Health Practice Manager in the Policy and Insights team at
Economist Impact in Singapore, where she is involved in projects ranging from
Breast Cancer, Fertility and Digital Health. Prior to this, she worked in
policy at the HFEA, the UK’s fertility regulator, leading projects related to
consent, the Code of Practice and clinic inspections. She also worked closely
with the Department of Health to outline the new upcoming legislation related
to extending the storage periods of gametes and embryos beyond 10 years.
Emily started her career as an embryologist at fertility clinics carrying out
diagnostic and micromanipulation procedures. Emily has a degree in Biology
from McGill University in Canada and a Master’s degree in Women’s Health from
University College London.
12:05 pm -12:50 SGT
ANTIMICROBIAL RESISTANCE: THE OVERLOOKED PANDEMIC AND ITS IMPLICATIONS FOR
PREVENTIVE CARE
Some 1.3m people died in 2019 from diseases caused by bacteria that have become
resistant to antibiotics. That is nearly as many as from malaria and HIV
combined. Greater antimicrobial resistance (AMR) has been driven by the
overprescription of antibiotics for non-serious diseases, and the economic
burden of superbugs is growing. In 2016 British government scientists predicted
that if no serious effort is made to check AMR, it could kill more than 10m
people a year globally by 2050. AMR has been deadliest in sub-Saharan Africa,
where it caused 24 deaths per 100,000 people in 2019, and South Asia (22 deaths
per 100,000). By 2018 South Asia’s 1.8 billion people were taking a quarter of
the world’s antibiotics. In most of the subcontinent antibiotics are easy to
obtain and are sometimes used to compensate for poor sanitation and healthcare.
More widely available cheap diagnostics would prevent doctors from prescribing
the wrong drugs. Better sanitation and healthcare would reduce demand for
antibiotics. Better medical training would curb overprescription. Fighting
superbugs may be costly, but failing to do so is costlier. In 2019
over-the-counter sales of antibiotics were banned in Islamabad, Pakistan’s
capital. What likely policy changes are needed to minimise the risk from AMR in
the future? What are some of the solutions to overprescription of antibiotics?
How and to what degree do regulatory oversight, supervision and risk management
need to change? Are more stringent, far-reaching regulatory mechanisms needed,
such as penalties for irrational prescription or overuse? Would a UN resolution
help solve the problem?
* View Profile
DAVID PATERSON
Professor, University of Queensland
bar1 bar2
DAVID PATERSON
Professor, University of Queensland
November 16th 2022
* 12:05 pm -12:50
Antimicrobial resistance: the overlooked pandemic and its implications for
preventive care
* View Profile
HSU LI YANG
Vice-dean (global health) and programme leader (infectious diseases), Saw
Swee Hock School Of Public Health, National University of Singapore
bar1 bar2
HSU LI YANG
Vice-dean (global health) and programme leader (infectious diseases), Saw
Swee Hock School Of Public Health, National University of Singapore
November 16th 2022
* 12:05 pm -12:50
Antimicrobial resistance: the overlooked pandemic and its implications for
preventive care
* View Profile
NORIO OHMAGARI
Director, Disease Control and Prevention Centre and AMR Clinical Reference
Centre, National Centre for Global Health and Medicine, Japan
bar1 bar2
NORIO OHMAGARI
Director, Disease Control and Prevention Centre and AMR Clinical Reference
Centre, National Centre for Global Health and Medicine, Japan
November 16th 2022
* 12:05 pm -12:50
Antimicrobial resistance: the overlooked pandemic and its implications for
preventive care
Norio Ohmagari has been director of the Disease Control and Prevention Centre
of the National Centre for Global Health and Medicine (NCGM), Japan, since
2012. NCGM is one of six national medical centres in Japan with infectious
diseases as the main focus. He also serves as director of the AMR Clinical
Reference Centre, which is commissioned by the Ministry of Health, Labour and
Welfare, Japan.
Dr Ohmagari joined NCGM in 2011, after serving as chief of the division of
infectious diseases at the Shizuoka Cancer Centre. He completed his clinical
fellowship in infectious diseases at the University of Texas, Houston.
Dr Ohmagari is engaged in the care, prevention and research of infectious
diseases from a global perspective. As a physician, he is directly involved
in the clinical management of patients with infectious diseases. Dr Ohmagari
is also actively working on activities related to controlling antimicrobial
resistance in Japan as well as the on-site response to infectious disease
crisis management in Japan.
* View Profile
MARY CHAN-PARK
Professor, School of Chemistry, Chemical Engineering and Biotechnology,
Nanyang Technological University, Singapore
bar1 bar2
MARY CHAN-PARK
Professor, School of Chemistry, Chemical Engineering and Biotechnology,
Nanyang Technological University, Singapore
*
November 16th 2022
* 12:05 pm -12:50
Antimicrobial resistance: the overlooked pandemic and its implications for
preventive care
MODERATED BY
* View Profile
NURIESYA SALEHA
Senior manager, health practice, Economist Impact
bar1 bar2
NURIESYA SALEHA
Senior manager, health practice, Economist Impact
November 15th 2022
* 03:40 pm -4:25
Supply chains: future-proofing for resilience in healthcare systems
November 16th 2022
* 12:05 pm -12:50
Antimicrobial resistance: the overlooked pandemic and its implications for
preventive care
Nuriesya Saleha is the senior manager of the health practice team for
Asia-Pacific at Economist Impact. She is a part of the policy and insights
team based in Singapore, working with multi-disciplinary teams across the
globe on projects spanning a range of disease focus areas. Ms Saleha has been
in the healthcare sector for nearly ten years. She previously worked at
Woodlands Health, an upcoming public healthcare campus in Singapore,
developing new clinical models and processes by engaging with various
clinical stakeholders. Prior to that, she was involved in
managed-care-related projects in Singapore and Malaysia at Fullerton Health,
and did health system operations and research at Johns Hopkins in Baltimore.
She has a master’s degree in health administration from Johns Hopkins
University and undergraduate degree in economics and biochemistry.
12:50 pm -1:50 SGT
NETWORKING LUNCH
2:00 pm -2:45 SGT
REMOVING SILOS: INTEGRATED DISEASE MANAGEMENT AND PERSONALISED CARE
Health systems, policies, funding streams and disease management are often
siloed. Personalised care focuses on a treatment plan that is customised for
each patient. It is also important to place additional emphasis on patient
values, needs and preferences. A growing issue in LMCs, comorbidities are
associated with higher costs and death rates for communicable diseases. Moving
from “sickcare” towards healthcare and patient-centricity promotes a more
holistic approach to health.
Infectious and non-communicable diseases are linked, and both are major
challenges across Asia that are often not managed in a holistic way. NCDs can
increase susceptibility to infections while infectious diseases can lead to
chronic ones. To improve patient quality of life, a more integrated model of
care should be implemented, where treatment considers the connection between a
condition and its comorbidities. Where can breaking down silos in treatment
foster efficiencies in the healthcare system? How can we mitigate the
inefficiency of having patients deal with multiple specialists and primary-care
appointments, and the lack of interoperability between different systems? What
is the optimal way to manage a patient with multiple illnesses?
* View Profile
CARMELIA BASRI
Vice chair, strategic and technical advisory group of tuberculosis,
WHO-SEARO, and senior adviser for HIV and TB programmes, USAID Indonesia
bar1 bar2
CARMELIA BASRI
Vice chair, strategic and technical advisory group of tuberculosis,
WHO-SEARO, and senior adviser for HIV and TB programmes, USAID Indonesia
*
November 16th 2022
* 02:00 pm -2:45
Removing silos: integrated disease management and personalised care
Carmelia Basri is a senior public health professional, senior epidemiologist
and independent grant management consultant with more than 35 years of work
experience implementing and providing technical input in the health sector in
Asia, and particularly in Indonesia. Ms Basri has solid experience providing
high-level technical advisory on TB and HIV disease control, policies,
strategies, activities, and monitoring and evaluation at regional and
national levels. She has a strong track record of working in an integrated
manner within an interdisciplinary and international team as well as engaging
with various stakeholders at all levels. She possesses a high degree of
integrity in health sector and development issues, with proven skills in
planning, analysis, co-ordination and problem-solving to establish
results-based programmes with government, the private sector, international
donors and civil-society organisations.
* View Profile
DAVID BOETTIGER
Senior research fellow, The Kirby Institute, University of New South Wales
bar1 bar2
DAVID BOETTIGER
Senior research fellow, The Kirby Institute, University of New South Wales
*
November 16th 2022
* 02:00 pm -2:45
Removing silos: integrated disease management and personalised care
* View Profile
JOANNE YOONG
Founder, Research for Impact
bar1 bar2
JOANNE YOONG
Founder, Research for Impact
*
November 16th 2022
* 02:00 pm -2:45
Removing silos: integrated disease management and personalised care
Joanne Yoong is an applied economist working at the intersection of
behavioural economics and health and financial decision-making for the
well-being of vulnerable populations. Ms Yoong’s primary appointment is as
senior economist at the University of Southern California (USC), where she
directs the offices of the USC Centre for Economic and Social Research in
Singapore and Washington, DC, and is a principal member of the USC
Behavioural Economics Studio.
Based in Singapore, Ms Yoong also holds faculty appointments at the Yong Loo
Lin School of Medicine at the National University of Singapore, the London
School of Hygiene and Tropical Medicine, Singapore Management University and
the RAND Corporation. She is the author of over 70 peer-reviewed articles in
leading economics, medical and public health journals.
In addition to her academic work, Ms Yoong is the founder of Research for
Impact, a Singapore-based social enterprise working to make behavioural and
social science research accessible, inclusive and transformative for all.
She received her PhD in economics at Stanford University as an FSI Starr
Foundation Fellow after an early career in financial services, and her AB
summa cum laude in economics and applied and computational mathematics from
Princeton University.
* View Profile
LEE CHIEN EARN
Deputy group chief executive (Regional Health System), Singapore Health
Services (SingHealth)
bar1 bar2
LEE CHIEN EARN
Deputy group chief executive (Regional Health System), Singapore Health
Services (SingHealth)
November 16th 2022
* 02:00 pm -2:45
Removing silos: integrated disease management and personalised care
MODERATED BY
* View Profile
GILLIAN PARKER
Senior manager, policy and insights, Economist Impact
bar1 bar2
GILLIAN PARKER
Senior manager, policy and insights, Economist Impact
November 16th 2022
* 02:00 pm -2:45
Removing silos: integrated disease management and personalised care
* 02:50 pm -3:35
Concurrent: Where’s your head at? Mental illness as the great unspoken
epidemic of our time
Gillian Parker is a senior manager for policy and insights at Economist
Impact and is currently based in Singapore. Previously she was deputy editor
for Eco-Business, a news site and business intelligence firm specialising in
sustainability issues across Asia.
Before moving to Singapore in 2019, she lived in sub-Saharan Africa for
nearly a decade. She worked in Johannesburg and Lagos as a risk analyst for
Control Risks, helping firms operate in challenging environments and navigate
regulatory and political instability, ethno-religious conflict and community
relations. Her other consulting work has included UKAID projects focusing on
policies, laws and regulations affecting businesses in Nigeria and
climate-resilient infrastructure in southern Africa. Before that, she
reported across a dozen countries for The Economist, Time and Voice of
America among other international news outlets. She was also a contributor to
the Economist Intelligence Unit, focusing on bespoke reports and indexes on
topics ranging from food security to small and medium-sized enterprises in
Nigeria and Islamic finance.
Ms Parker has a master’s degree in African and Asian politics from SOAS and
hails originally from Northern Ireland.
2:00 pm -2:45 SGT
CONCURRENT: THE FUTURE OF CANCER CARE
A survey of 61 countries published in The Lancet concluded that one-seventh of
planned cancer surgeries have been delayed in regions that experienced covid-19
lockdowns. Medical advances now hold the hope of prolonged life, or even cures,
for a growing if still small number of patients in cancer care. What is the
state of cancer treatment after the pandemic? Can cancer be cured? Which cancers
need our urgent attention in Asia? What is the disease burden, as well as the
economic and social burden, of cancer in the region? What are the latest
advances in cancer diagnostics and treatment, and what is their impact and
return on investment? How well are countries across the region addressing the
challenge? Who is paying for the latest innovations? As the aftermath of
covid-19 begins to recede, we will take a closer look at the strengths and
weaknesses of Asia’s response to cancer.
* View Profile
HUREN SIVARAJ
Co-founder and chief executive, Oncoshot
bar1 bar2
HUREN SIVARAJ
Co-founder and chief executive, Oncoshot
*
*
November 16th 2022
* 02:00 pm -2:45
Concurrent: The future of cancer care
Huren Sivaraj is a medical oncologist whose work falls at the intersection of
health informatics and oncology. Oncoshot, which was founded in 2018, is a
first-in-class real-time aggregated insights-sharing marketplace for clinical
research stakeholders to plan and manage cancer trials. The company’s mission
is to improve patient access to cutting-edge cancer research by addressing
enterprise-level inefficiencies arising from a lack of real-time cancer
population insights during clinical research planning. Oncoshot’s core
principles centre around providing academic and private cancer centres with
the security, privacy and control measures required for scalable insights
sharing between hospitals and industry stakeholders. Its technology applies
federated data systems, artificial intelligence and machine learning to
oncology patient data. Locally, Oncoshot supports public and private cancer
research stakeholders as the technology platform behind the Project EISE
(pronounced “easy”) ecosystem. By facilitating safe and secure aggregated
insights exchange, Project EISE boosts the outreach of Singapore’s research
institutes to global pharma, biotech and contract research organisations.
This provides cancer patients in Singapore with access to a wider set of
clinical trial options at every point in a cancer treatment journey. The
company has expanded to Australia and India since its inception, highlighting
its applicability and success.
* View Profile
MARY WONG-HEMRAJANI
Chairman, Global Chinese Breast Cancer Organisations Alliance
bar1 bar2
MARY WONG-HEMRAJANI
Chairman, Global Chinese Breast Cancer Organisations Alliance
November 16th 2022
* 02:00 pm -2:45
Concurrent: The future of cancer care
Mary Wong-Hemrajani is the current chairman of the Global Chinese Breast
Cancer Organisations Alliance (GCBC). She is also a breast cancer survivor
and has over 30 years’ experience in management and corporate finance roles.
She served as chief executive for several multinational companies before
devoting herself full time to volunteer work to support breast cancer
patients. In 2017 Ms Wong-Hemrajani was named Survivor of the Year and
received an award from the Susan G Komen Breast Cancer Foundation for her
outstanding performance and service to promote education, patient support and
screening of breast cancer. Recently, she was nominated to be a panellist for
the Breast Cancer Initiative Working Group of the World Health Organisation.
After becoming a volunteer, Ms Wong-Hemrajani completed several professional
courses in patient support, strengthening the capacity and management of
patients’ groups. As chairman of GCBC, she initiated the Pink Angels service,
a free service whereby “pink angel” breast cancer survivors accompany
patients through treatment, offering peer support and encouragement. During
the covid-19 pandemic, she developed a series of online support services for
breast cancer patients and promoted the Pink Academy, an online workshop to
raise breast cancer awareness and promote breast health and positive
survivorship.
* View Profile
PIERCE CHOW
Professor and programme director, Duke-NUS Medical School, Singapore, and
senior consultant surgeon, National Cancer Centre Singapore and Singapore
General Hospital
bar1 bar2
PIERCE CHOW
Professor and programme director, Duke-NUS Medical School, Singapore, and
senior consultant surgeon, National Cancer Centre Singapore and Singapore
General Hospital
*
November 16th 2022
* 02:00 pm -2:45
Concurrent: The future of cancer care
Pierce Chow is a professor and programme director at the Duke-NUS Medical
School and senior consultant surgeon at the National Cancer Centre Singapore
(NCCS) and the Singapore General Hospital. He is concurrently a National
Medical Research Council (NMRC)–funded senior clinician scientist and was the
founding president of the College of Clinician Scientists, Academy of
Medicine Singapore.
After completing his surgical residency and PhD, Professor Chow trained in
liver transplantation in Australia. On top of his busy clinical practice in
hepato-pancreato-biliary surgery, he has been very active in clinical and
translational research in liver cancer.
He co-founded the Asia-Pacific Hepatocellular Carcinoma trials group and has
been the protocol chair of nine prospective multi-centre clinical studies in
liver cancer over the past 20 years. He has led the multi-disciplinary NMRC
Translational and Clinical Research National Flagship Programme in Liver
Cancer since 2016. He is also a faculty member at the Genome Institute of
Singapore and the SingHealth Duke-NUS Global Health Institute, and research
director at the Institute of Cell and Molecular Biology Singapore.
He is also very active in medical education and was the inaugural course
director of the human structure and function course in the MD programme of
the Duke-NUS Medical School (2007–19). He is also the inaugural director of
the PhD programme in clinical and translational sciences at Duke-NUS (since
2018). Professor Chow is on the faculty of the surgery residency programme at
SingHealth and continues to be course director for advanced trauma life
support courses.
MODERATED BY
* View Profile
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
bar1 bar2
DAVID HUMPHREYS
Global practice leader, health policy, Economist Impact
November 15th 2022
* 09:10 am -9:35
Ministerial keynote interview: a view from Indonesia
* 09:40 am -9:55
Spotlight interview
* 10:05 am -10:20
Exclusive keynote: Future of healthcare outlook
* 10:25 am -11:10
Panel: Removing silos—collaborating for success in health
* 11:45 am -12:30
Incentivising health: fostering value-based care
* 01:50 pm -2:35
Elevating access: financing health and universal healthcare
* 02:40 pm -3:05
Keynote interview
November 16th 2022
* 10:00 am -10:45
Balancing lives and livelihoods: preparedness for future pandemics in the
aftermath of covid-19
* 10:50 am -11:35
Jabs for the jab-nots: the future of open-source vaccines, mRNA and beyond
* 02:00 pm -2:45
Concurrent: The future of cancer care
David Humphreys is the global practice leader, health policy, Economist
Impact. He leads a multidisciplinary team that conducts high quality clinical
and policy analyses to inform micro level health decision making and produce
macro level perspectives. Supporting clients across the health ecosystem for
internal and external strategy making, David develops and directs engagements
on such issues as evidence-based reviews of new health technologies, future
healthcare challenges, value-based healthcare approaches for specific
therapeutic areas, and impact of new policy initiatives.
Previously, David held multiple roles at The EIU, first as the Americas
Director of Custom Research managing a business that delivered projects on
public policy and market strategy, and then as the Head of EIU Healthcare in
the US. Prior to joining The EIU, he was the senior director of Latin America
at Frost & Sullivan, where he led strategic analyses in industries such as
ICT and Healthcare, and spearheaded the firm’s expansion into the region. He
also served as a senior adviser at Management Partners, a consulting firm for
municipal governments in the US.
David holds an MBA degree and an honours certificate in international
business diplomacy from Georgetown University, and a BA in economics from
Ohio Wesleyan University. He has participated as a speaker at various
healthcare conferences, given lectures at academic institutions, led
strategic workshops and directed numerous expert panels with senior level
executives.
2:50 pm -3:35 SGT
CONCURRENT: WHERE’S YOUR HEAD AT? MENTAL ILLNESS AS THE GREAT UNSPOKEN EPIDEMIC
OF OUR TIME
More than 700,000 people lose their life to suicide every year, and the world is
likely to miss a 2030 target of reducing suicide by one-third. In 2005, and
later in 2012, the WHO adopted resolutions promoting a comprehensive,
co-ordinated response to mental health from the health and social sectors of
member states. In June 2021 it issued an implementation guide for suicide
prevention in these countries. This was based on a revised mental health action
plan for 2013-2030, which states that all countries need to take action to
prevent suicide through a comprehensive national strategy. Where is the problem
of suicide most acute? How can mental health stigma be reduced? If what gets
measured gets managed, how do we quantify mental health issues? Who will pay for
mental health treatment? What mental health solutions are insurance leaders
already offering to enterprise clients, and what are the barriers to
implementing them?
* View Profile
ANTHEA ONG
Former nominated member, Parliament Of Singapore, and Founder and
chairperson, WorkWell Leaders
bar1 bar2
ANTHEA ONG
Former nominated member, Parliament Of Singapore, and Founder and
chairperson, WorkWell Leaders
*
*
November 16th 2022
* 02:50 pm -3:35
Concurrent: Where’s your head at? Mental illness as the great unspoken
epidemic of our time
* View Profile
JANICE WENG HUIQIN
Senior assistant director, MOH Office for Healthcare Transformation,
Singapore
bar1 bar2
JANICE WENG HUIQIN
Senior assistant director, MOH Office for Healthcare Transformation,
Singapore
*
November 16th 2022
* 02:50 pm -3:35
Concurrent: Where’s your head at? Mental illness as the great unspoken
epidemic of our time
* View Profile
JIANG LONG
Director, Office of Cooperation and Collaboration, Shanghai Mental Health
Center, Shanghai Jiao Tong University School of Medicine
bar1 bar2
JIANG LONG
Director, Office of Cooperation and Collaboration, Shanghai Mental Health
Center, Shanghai Jiao Tong University School of Medicine
*
*
November 16th 2022
* 02:50 pm -3:35
Concurrent: Where’s your head at? Mental illness as the great unspoken
epidemic of our time
* View Profile
NEERJA BIRLA
Founder and chairperson, MPower
bar1 bar2
NEERJA BIRLA
Founder and chairperson, MPower
November 16th 2022
* 02:50 pm -3:35
Concurrent: Where’s your head at? Mental illness as the great unspoken
epidemic of our time
An inspiring personality, Neerja Birla is a progressive, dynamic and
versatile leader, driven by her passions and an unwavering resolve to give
back to society responsibly. A passionate educationist and a mental health
champion, Mrs Birla is the founder and chairperson of Aditya Birla Education
Trust (ABET), a social enterprise that endeavours to positively impact the
lives of people from all sections of society and bring about progressive
change in the field of education and on the mental health landscape of India.
Mrs Birla currently holds the global chair of mental health at the G100, an
eminent and empowered club of the top 100 women leaders in the world with a
vision for the future, in regards to inclusivity and the economic and social
empowerment of women globally. A firm supporter of gender equality in
society, she is also a member of the Asia Gender Network, the first pan-Asian
network committed to mobilising capital for gender equality. She also serves
as a trustee of the Mumbai Police Foundation.
Mrs Birla holds a bachelor of science honours degree in psychology from the
University of Derby, UK.
MODERATED BY
* View Profile
GILLIAN PARKER
Senior manager, policy and insights, Economist Impact
bar1 bar2
GILLIAN PARKER
Senior manager, policy and insights, Economist Impact
November 16th 2022
* 02:00 pm -2:45
Removing silos: integrated disease management and personalised care
* 02:50 pm -3:35
Concurrent: Where’s your head at? Mental illness as the great unspoken
epidemic of our time
Gillian Parker is a senior manager for policy and insights at Economist
Impact and is currently based in Singapore. Previously she was deputy editor
for Eco-Business, a news site and business intelligence firm specialising in
sustainability issues across Asia.
Before moving to Singapore in 2019, she lived in sub-Saharan Africa for
nearly a decade. She worked in Johannesburg and Lagos as a risk analyst for
Control Risks, helping firms operate in challenging environments and navigate
regulatory and political instability, ethno-religious conflict and community
relations. Her other consulting work has included UKAID projects focusing on
policies, laws and regulations affecting businesses in Nigeria and
climate-resilient infrastructure in southern Africa. Before that, she
reported across a dozen countries for The Economist, Time and Voice of
America among other international news outlets. She was also a contributor to
the Economist Intelligence Unit, focusing on bespoke reports and indexes on
topics ranging from food security to small and medium-sized enterprises in
Nigeria and Islamic finance.
Ms Parker has a master’s degree in African and Asian politics from SOAS and
hails originally from Northern Ireland.
2:50 pm -3:35 SGT
HEALTHSPAN OVER LIFESPAN: MITIGATING THE DISEASES OF AGEING
By 2025 Asia will have more than 450m seniors aged 65 years and over, making up
10% of the population. Understanding and tackling the diseases of ageing will
lessen the time at the end of many people’s lives that is spent in pain and
discomfort. Illnesses in the crosshairs of healthcare leaders include cognitive
disorders and neurodegeneration, diabetes and associated metabolic problems, and
cancer. Dealing with these might not greatly extend average lifespans but would
surely increase what is known in the argot as healthspan.
There is enormous potential in Yamanaka Shinya’s work on a set of proteins, the
Yamanka factors, that can give differentiated cells the ability that embryonic
stem cells have to turn into other kinds of cells. The prospect is of a
limitless supply of genetically matched cells for anyone who needs an organ
replacement. But what are the social, political, regulatory and environmental
implications of increasing longevity using this and other methods? Where can
digital tools help citizens live longer, healthier lives? What other innovations
are on the horizon for the “silver economy”? How can healthy ageing initiatives
lead the way in the growing field of preventive, community-based care? Where
does life-course theory, which looks at ageing across the entire age spectrum,
overlap with notions of preventive care?
* View Profile
ANA LLENA-NOZAL
Senior economist, Organisation for Economic Co-operation and Development
(OECD)
bar1 bar2
ANA LLENA-NOZAL
Senior economist, Organisation for Economic Co-operation and Development
(OECD)
*
November 16th 2022
* 02:50 pm -3:35
Healthspan over lifespan: mitigating the diseases of ageing
* View Profile
PAULIN STRAUGHAN
Director, Centre for Research on Successful Ageing (ROSA), Singapore
Management University
bar1 bar2
PAULIN STRAUGHAN
Director, Centre for Research on Successful Ageing (ROSA), Singapore
Management University
November 16th 2022
* 02:50 pm -3:35
Healthspan over lifespan: mitigating the diseases of ageing
* View Profile
RINTARO MORI
Regional advisor on population ageing and sustainable development, United
Nations Population Fund
bar1 bar2
RINTARO MORI
Regional advisor on population ageing and sustainable development, United
Nations Population Fund
*
November 16th 2022
* 02:50 pm -3:35
Healthspan over lifespan: mitigating the diseases of ageing
Professor Rintaro Mori is regional adviser on population ageing and
sustainable development at the UNFPA Asia-Pacific office. After paediatric
training in Japan, he practised in Australia, Nepal and the UK as a senior
physician and studied epidemiology and public health at the London School of
Hygiene and Tropical Medicine before being involved in guideline development
for NICE, UK. He has also actively been involved in research and aid work in
Madagascar, Bangladesh and Mongolia, as well as research in health systems
and women’s and children’s health at the both national and the global levels.
He was appointed director of the department of health policy at the National
Centre for Child Health and Development and professor in health policy for
families and children at Kyoto University, where he pursed his research on
the life-course approach to achieve sustainable social and health-care
systems in the context of population ageing, before taking up his current
role in 2018.
MODERATED BY
* View Profile
EMILY TIEMANN
Manager, health practice, Economist Impact
bar1 bar2
EMILY TIEMANN
Manager, health practice, Economist Impact
November 15th 2022
* 08:00 am -9:00
Private roundtable - Personalised healthcare at scale: technology lessons
for equity post-pandemic
* 04:30 pm -5:10
Enabling the patient voice
November 16th 2022
* 12:05 pm -12:50
Concurrent: Women’s health: building a roadmap for equity
* 02:50 pm -3:35
Healthspan over lifespan: mitigating the diseases of ageing
Emily Tiemann is a Health Practice Manager in the Policy and Insights team at
Economist Impact in Singapore, where she is involved in projects ranging from
Breast Cancer, Fertility and Digital Health. Prior to this, she worked in
policy at the HFEA, the UK’s fertility regulator, leading projects related to
consent, the Code of Practice and clinic inspections. She also worked closely
with the Department of Health to outline the new upcoming legislation related
to extending the storage periods of gametes and embryos beyond 10 years.
Emily started her career as an embryologist at fertility clinics carrying out
diagnostic and micromanipulation procedures. Emily has a degree in Biology
from McGill University in Canada and a Master’s degree in Women’s Health from
University College London.
3:45 pm -4:15 SGT
COFFEE BREAK AND NETWORKING
* Full Day
* Plenary
Plenary
9:00 am -9:30 SGT
KEYNOTE - VOICES: THE FUTURE OF ARTIFICIAL INTELLIGENCE AND HEALTHCARE
Is healthcare ready for artificial intelligence (AI)? While modern healthcare
areas are more and more digitised and ready for AI, there are still visible gaps
for sufficient and well-labelled data. In the coming years, we may expect
visible breakthroughs in AI drug discovery, medical robots, AI pathology,
multi-omics and diagnostic AI, personalised treatment, and even AI in longevity
research. Glean insights from the frontier of AI advancements from both a global
perspective as well as with insights from China.
Keynote available for broadcast and on-demand for November 17 only.
* View Profile
KAI-FU LEE
Chairman and chief executive, Sinovation Ventures, and President, Sinovation
Ventures Artificial Intelligence Institute
bar1 bar2
KAI-FU LEE
Chairman and chief executive, Sinovation Ventures, and President, Sinovation
Ventures Artificial Intelligence Institute
*
November 17th 2022
* 09:00 am -9:30
Keynote - Voices: the future of artificial intelligence and healthcare
Kai-Fu Lee is the chairman and chief executive of Sinovation Ventures and
president of Sinovation Ventures Artificial Intelligence Institute.
Sinovation Ventures, managing US$3bn dual-currency investment funds, is a
leading venture capital firm focusing on developing next-generation deep-tech
companies in China. Prior to founding Sinovation in 2009, Mr Lee was the
president of Google China and a senior executive at Microsoft, SGI and Apple.
He has been working in the areas of artificial intelligence research,
development and investment for more than 30 years. In the field of artificial
intelligence, Mr Lee built one of the first game-playing programs to defeat a
world champion (1988, Othello), as well as the world’s first
large-vocabulary, speaker-independent continuous speech recognition system.
He founded Microsoft Research China, later renamed Microsoft Research Asia.
While with Apple, he led AI projects in speech and natural language. Mr Lee
has authored ten US patents and more than 100 journal and conference papers.
Mr Lee is co-chair of the Artificial Intelligence Council and the World
Economic Forum Centre for the Fourth Industrial Revolution, and he is a
fellow of the Institute of Electrical and Electronics Engineers (IEEE). He
received a bachelor’s degree in computer science from Columbia University and
a PhD from Carnegie Mellon University, as well as honorary doctorate degrees
from both Carnegie Mellon and the City University of Hong Kong.
9:30 am -10:00 SGT
IN CONVERSATION WITH HEALTHCARE REGULATORS
It is argued that regulation does not hinder innovation in healthcare platforms,
but rather raises standards and therefore increases value. More regulatory
clarity makes products more competitive. Technology is worth more when evidence
backs its claims of effectiveness. But technology almost always outpaces
regulation. Covid-19 has removed multiple institutional and cultural barriers to
the adoption of digital solutions in healthcare, though some remain. A big
reason why it has taken so long for consumer technology to disrupt healthcare is
that the highly regulated sector does not lend itself to Silicon Valley’s “move
fast and break things” credo. Regulators, for their part, are trying to move
faster themselves. A recent improvement is the introduction of regulation around
software as a medical device in most major Asia-Pacific jurisdictions, which
limits the claims developers can make around the health impacts of their
products. In February 2021 the Australian department of health, via the
Therapeutic Goods Administration, introduced several exclusions and exemptions
aimed at reducing unnecessary regulatory burdens for specific types of software
products. Where is healthcare on its digital transformation journey in the
Asia-Pacific and beyond? Where can data privacy and regulation enable innovation
in healthcare technology?
* View Profile
BUDI WIWEKO
Chairman, National Health Technology Assessment Committee, Ministry of
Health, Indonesia
bar1 bar2
BUDI WIWEKO
Chairman, National Health Technology Assessment Committee, Ministry of
Health, Indonesia
*
November 17th 2022
* 09:30 am -10:00
In conversation with healthcare regulators
* View Profile
JOHN LIM
Executive director, Duke-NUS Centre of Regulatory Excellence and Chairman,
Consortium for Clinical Research and Innovation, Singapore
bar1 bar2
JOHN LIM
Executive director, Duke-NUS Centre of Regulatory Excellence and Chairman,
Consortium for Clinical Research and Innovation, Singapore
November 17th 2022
* 09:30 am -10:00
In conversation with healthcare regulators
MODERATED BY
* View Profile
EMI MICHAEL
Global health manager, Economist Impact
bar1 bar2
EMI MICHAEL
Global health manager, Economist Impact
November 17th 2022
* 09:30 am -10:00
In conversation with healthcare regulators
Emi is a manager in the Health Policy and Insights team at Economist Impact.
She has a special interest in health inequalities and the social determinants
of health. Emi is a global health research strategist and has a wealth of
experience in global health research, policy and programming. Her expertise
in global health advisory, program design and healthcare communications mean
that Emi brings a breadth of experience to the team across technical areas.
Her current role involves exploratory research using economic models, rapid
reviews of scientific papers and development of a global index on health
inclusivity. Emi also designs and works on longer term research assignments
across the international development sphere, including in the Education and
WASH sectors.
Emi has experience working across sectors, having held various roles across
the health and social care industry, serving as a Health Inequalities Manager
within the UK Department of Health and Social Care, Consultant Epidemiologist
with the World Health Organisation under the Health Securities and
Preparedness Division and as a Technical Delivery Officer with UNICEF. Emi
has an undergraduate degree in Biomedical Science from the University of
Warwick and a Master in Public Health from Imperial College London.
10:00 am -10:15 SGT
ACTION HOUR - CASE STUDIES: DIGITISING PATIENT CONSENT IN A DECENTRALISED WORLD
Hear how the Concentric team experienced, first hand, the problems associated
with consenting patients for medical procedures using traditional paper-based
systems. Learn how this in-depth knowledge enabled them to re-think, re-design
and digitise the consent process and improve shared decision making. Understand
how clinician and user feedback was utilised to help iterate and refine the
product. They will discuss how the consent process has been optimised and will
describe their innovator journey from first use to overcoming barriers of
adoption.
* View Profile
EDWARD ST JOHN
Co-founder and chief medical officer, Concentric Health
bar1 bar2
EDWARD ST JOHN
Co-founder and chief medical officer, Concentric Health
*
*
November 17th 2022
* 10:00 am -10:15
Action hour - case studies: digitising patient consent in a decentralised
world
10:15 am -10:30 SGT
ACTION HOUR - CASE STUDIES: FOSTERING MENTAL WELLNESS THROUGH COMMUNICATIONS
TECHNOLOGY ACCESS FOR MIGRANT POPULATIONS
* View Profile
MEERA SACHDEVA
Co-founder, Call Home
bar1 bar2
MEERA SACHDEVA
Co-founder, Call Home
November 17th 2022
* 10:15 am -10:30
Action hour - case studies: fostering mental wellness through
communications technology access for migrant populations
10:30 am -11:10 SGT
IN CONVERSATION… WHAT’S NEXT IN BIOTECH AND DIGITAL HEALTHCARE INNOVATIONS
Technological breakthroughs promise to change how we produce food, look after
the sick and tackle climate change. Concerted action against covid-19 has
brought together decades of cumulative scientific progress, with profound
effects on the future of medicine. Technologies such as CRISPR gene editing will
cure hereditary diseases, produce disease-resistant crops and enable the
breeding of malaria-free mosquitos. Scientific advances in fields such as gene
sequencing and AI make new modes of care possible. Digital devices and treatment
pathways can also enhance treatment recommendations and with them patient
outcomes, as complex algorithms work on data to streamline decision-making. With
the covid-19 crisis spurring technological advancements, gaps in digital
inclusivity must be closed as healthtech innovations push the physical and the
digital together. What part will the metaverse play in the future of healthcare?
Will it have a greater effect on B2B or B2C products? Is Asia better placed than
the West to leapfrog in innovations because it has fewer legacy systems? What
innovations are on the horizon in biotech and digital tech? To what extent will
new market entrants change the roles that incumbents and multinational
corporations play? What models can traditional healthcare platforms consider
adopting to stay relevant in coming years? How can innovative start-ups and
established companies maximise their opportunities in healthtech?
* View Profile
FARHAD IMAM
Director, health and life sciences, Gates Ventures
bar1 bar2
FARHAD IMAM
Director, health and life sciences, Gates Ventures
November 17th 2022
* 10:30 am -11:10
In conversation… What’s next in biotech and digital healthcare innovations
* View Profile
ROBERTA SARNO
Director of digital health, Asia Pacific Medical Technology Association
(APACMed)
bar1 bar2
ROBERTA SARNO
Director of digital health, Asia Pacific Medical Technology Association
(APACMed)
*
November 17th 2022
* 10:30 am -11:10
In conversation… What’s next in biotech and digital healthcare innovations
MODERATED BY
* View Profile
SANTOS DAS
Manager, global health, Economist Impact
bar1 bar2
SANTOS DAS
Manager, global health, Economist Impact
November 17th 2022
* 10:30 am -11:10
In conversation… What’s next in biotech and digital healthcare innovations
Mr. Santos is part of the Economist Impact’s Health Practice team with
primary focus on health policy and research. He is a public health subject
matter and domain expert with over 14 years of diverse experience in
consulting, industry, non-profits and public sector. Santos is well steeped
in the area of global health, prior to joining Economist Impact; he was part
of various healthcare projects in India, Middle East and Africa. He has
worked across the health ecosystem, from leading research projects on digital
health and PPP evaluation for Apollo Hospitals to MENA pharma market dynamics
at Ernst & Young and with UNICEF as part of the WASH program. Mr. Santos has
published multiple research articles on digital health and telemedicine.
Mr. Santos has completed his Masters in International Public Health from
Liverpool School of Tropical Medicine, UK and Masters in Social Work from
Tata Institute of Social Sciences, India.
11:15 am -12:00 SGT
THE PATIENT WILL SEE YOU NOW: HEALTHCARE AS A CONSUMER PRODUCT IN THE ANYWHERE
ECONOMY
The pandemic hastened a paradigm shift in healthcare where digital tools are
readily created and used to modify the process of care. Patients no longer rely
exclusively on a medical professional as a gatekeeper. The new trend towards
healthcare on demand has immense potential in Asia and beyond. Healthcare is
turning into a consumer product. AI, digital diagnostics and telehealth are key
to this movement, along with a new wave of capital flooding into a vast
industry. Costly, highly regulated health systems are being shaken up by firms
that target patients directly and meet them where they are—which is increasingly
online. E-pharmacies fulfil prescriptions, wearable devices monitor health in
real time, telemedicine platforms connect patients with physicians and home
tests enable self-diagnosis. Big tech collectively poured some $3.6 billion into
health-related deals last year.
They are particularly active in two areas of healthcare: devices and data.
Automating aspects of the value chain can free HCPs to see more patients with
urgent needs. In a few key Chinese cities, the hospital can come to the patient,
with decentralised devices augmented by the occasional in-person nurse visit.
This is part of the wider trend of healthcare moving beyond tertiary
institutions and hospitals to homes and the community. Is the “patient pathway
cliff” the new patent cliff? The consumer-health boom has hit some snags. The
Theranos saga offers a cautionary tale of how tricky biology is, compared with
much computer science. Do legacy healthcare systems risk being left behind if
they don’t digitise? What will traditional healthcare players need to do to
reinvent themselves as platforms? What are the ethical, social and legal
concerns and risks associated with AI-based systems? Will increasing regulatory
oversight help or hinder digital health? Can we trust algorithms to make
life-and-death decisions? To what extent can we use AI systems to build capacity
and free time for HCPs? How do we mitigate the challenges of scarce talent, the
need to establish data privacy, and the complexity of regulation and compliance?
What policy changes are likely to be needed to support the benefits of big
tech’s move into healthcare while minimising the risks to consumers? How does
empowering patients foster the development of preventive healthcare?
* View Profile
BRONWYN LE GRICE
Chief executive and managing director, ANDHealth
bar1 bar2
BRONWYN LE GRICE
Chief executive and managing director, ANDHealth
*
*
November 17th 2022
* 11:15 am -12:00
The patient will see you now: healthcare as a consumer product in the
anywhere economy
Bronwyn Le Grice has over 18 years of executive experience in the health
technology sector spanning commercialisation, venture capital, capital
raising and industry advocacy. Formerly an investment director with a leading
health-care venture capital firm, BioScience Managers, between 2012 and 2017
she managed over $65m of private and public equity capital raisings and was
actively involved in portfolio investments of over $30m.
In 2017, working with a consortium of industry partners, Ms Le Grice created
ANDHealth, Australia’s only commercialisation organisation dedicated to
digital health, with a specific focus on digital medicine and digital
therapeutics. The novel ANDHealth+ programme, piloted in 2018–19, supported
ten companies to go on to raise over $47m, create 296 jobs and impact more
than 200,000 patients in under four years.
Ms Le Grice is a non-executive director of Lumos Diagnostics and holds
various advisory roles, including with the Australia New Zealand Leadership
Forum Health Technology Sector Group, Swinburne University’s Innovation
Precinct advisory board, the RMIT University Health and Biomedical Sector
Expert Research Advisory Group and the NSW Cyber Security Standards
Harmonisation Task-Force. In 2020 she received the Most Valuable Woman in
Leadership Award by the BioMelbourne Network.
* View Profile
CHRIS JIA
Vice-president, digital growth, United Family Healthcare
bar1 bar2
CHRIS JIA
Vice-president, digital growth, United Family Healthcare
November 17th 2022
* 11:15 am -12:00
The patient will see you now: healthcare as a consumer product in the
anywhere economy
* View Profile
JONATHAN LEY
Assistant director, InHealth and Finance Redesign, MOH Office for Healthcare
Transformation, Singapore
bar1 bar2
JONATHAN LEY
Assistant director, InHealth and Finance Redesign, MOH Office for Healthcare
Transformation, Singapore
*
November 17th 2022
* 11:15 am -12:00
The patient will see you now: healthcare as a consumer product in the
anywhere economy
MODERATED BY
* View Profile
JOCELYN HO
Health policy analyst, health practice, Economist Impact
bar1 bar2
JOCELYN HO
Health policy analyst, health practice, Economist Impact
November 17th 2022
* 11:15 am -12:00
The patient will see you now: healthcare as a consumer product in the
anywhere economy
Jocelyn is a health policy analyst in the Policy and Insights team at
Economist Impact in Hong Kong. She is involved in projects that span the Asia
Pacific region as well as globally. Her interests lies in cancer and mental
health but she has worked on projects related to bone health, rare diseases
and childhood vaccinations. Prior to joining Economist Impact, Jocelyn worked
as a radiation therapist delivering radiation treatments to cancer patients
in Canada. Jocelyn holds a degree in Medical Radiation Sciences from McMaster
University in Canada and a Master’s degree in Global Health and Development
from University College London.
12:05 pm -12:50 SGT
DATA AND INTEROPERABILITY IN HEALTHCARE: ETHICS, OPPORTUNITIES AND THE WAY
FORWARD
Data will be one of the most important commodities in healthcare in 2022.
Healthcare consumers and patients are increasingly custodians of their own data
and expect to access healthcare on demand—anywhere and anytime. To analyse that
data, healthcare providers, payers and suppliers will increasingly rely on
machine-learning algorithms and software to improve diagnoses, treatment and
outcomes. Regulators—focusing on issues around data security and privacy, as
well as competition and intellectual-property rights—will struggle to keep up.
The value of data arguably lies in offering real-time visibility and remote
access, and in its being analysed or manipulated by various entities. Pioneering
healthcare firms are looking to elevate and future-proof their IT
infrastructure, cyber-security and workflows to enhance efficiency and improve
patient outcomes.
The demand for more data “sovereignty” to comply with evolving local laws,
attempts to balance an improved experience for customers with efforts to keep
their data safe, and the roll-out of new technology in an evolving regulatory
environment are among the myriad shifts that present challenges for IT
decision-makers in healthcare. Privacy imperatives and regulation can both
enable and stymie the adoption of technology and innovation. In the early days
of the covid-19 pandemic, companies augmented the work of multilateral
organisations and opened swathes of proprietary data to the public so things
like the severity of lockdowns could be measured.
Keeping China mostly free of covid-19 for some time has cost residents a good
deal of privacy, especially around their data. Those with smartphones must scan
QR codes to enter public buildings or catch a taxi, train or domestic flight. Is
the loss of data privacy a fair cost of government interventions in public
health? What are the potential drawbacks of relying on data as a tool? Will
increasing data collection drive the emergence of surveillance states? If what
gets measured gets managed, which data gaps need plugging to enable optimal
healthcare? What implications do Web 3.0 and zero-party data have for data
ownership, privacy and application development? What progress has been made
towards an interoperable digital platform for patient identity? How else can
healthcare platforms digest today’s deluge of data? What should leaders be doing
to encourage the de-siloing of organisations and their data to harvest insights?
Should data be considered a public good? Can we ask patients for more lifestyle
data to deliver better treatment? What are the ethical and legal concerns here?
And is data privacy killing patients?
* View Profile
ANDREI BLAJ
Co-founder and chief operations officer, Medicai
bar1 bar2
ANDREI BLAJ
Co-founder and chief operations officer, Medicai
*
*
*
November 17th 2022
* 12:05 pm -12:50
Data and interoperability in healthcare: ethics, opportunities and the way
forward
* View Profile
RUMA BHARGAVA
Country lead, health care, C4IR India, World Economic Forum, and professor,
Manipal University
bar1 bar2
RUMA BHARGAVA
Country lead, health care, C4IR India, World Economic Forum, and professor,
Manipal University
*
*
*
November 17th 2022
* 12:05 pm -12:50
Data and interoperability in healthcare: ethics, opportunities and the way
forward
Ruma Bhargava is a public health and social impact professional working in
policy, advocacy, research and implementation of strategies. A Chevening
fellow from the University of Oxford, she currently leads the India
health-care vertical of the World Economic Forum and serves as an adjunct
professor at Manipal University. Dr Ruma also heads Samarpann, a
non-governmental organisation working in rural and tribal India to ensure
health, education and livelihood.
Dr Ruma has worked with the International Red Cross to define policies for
covid-19 relief across the Asia-Pacific region and earlier with the
government of India to conceptualise strategies for India’s Universal
Immunisation Programme reaching 26m children and 30m pregnant women annually.
She regularly consults with multiple stakeholders, including the UN,
government and civil society in domains of health systems strengthening,
maternal and child health, communicable and non-communicable diseases, and
digital health.
She holds an MBA from Nanyang Technological University, Singapore, a master’s
degree in public health and a bachelor of dental surgery from Manipal
University.
* View Profile
TENG LIAW
Emeritus professor of general practice and health informatics, and head of
the WHO Collaborating Centre for eHealth, UNSW Sydney
bar1 bar2
TENG LIAW
Emeritus professor of general practice and health informatics, and head of
the WHO Collaborating Centre for eHealth, UNSW Sydney
*
November 17th 2022
* 12:05 pm -12:50
Data and interoperability in healthcare: ethics, opportunities and the way
forward
Teng Liaw is a general practitioner, health informatician and clinician
scientist. He heads the World Health Organisation (WHO) Collaborating Centre
for eHealth and works with WHO headquarters and WPRO on national digital
capability maturity and readiness in digital health development,
interoperability, implementation and quality improvement. He collaborates
with and is a member of the I-DAIR (International Digital Health and AI
Research Collaborative) independent review panel.
Dr Liaw is a global thought leader and has edited journals and published
extensively on electronic decision support, mobile health, digital health
maturity models, data quality and interoperability through common data
models, socio-ethical issues in artificial intelligence and machine learning,
governance (clinical and data), and environment and corporate social
responsibility.
He is a founding fellow of the International Academy of Health Science
Informatics and Australian College of Health Informatics/Institute of Digital
Health. He is an elected international fellow of the American College of
Medical Informatics. He chairs the International Medical Informatics
Association Primary Care Informatics Working Group and the Royal Australian
College of General Practitioners National Research and Evaluation Ethics
Committee.
MODERATED BY
* View Profile
CHEE HEW
Director, data analytics and consulting, Clearstate, EIU Healthcare
bar1 bar2
CHEE HEW
Director, data analytics and consulting, Clearstate, EIU Healthcare
November 15th 2022
* 05:15 pm -6:00
DEI in the DNA: improving diversity, equity and inclusion in healthcare
November 17th 2022
* 12:05 pm -12:50
Data and interoperability in healthcare: ethics, opportunities and the way
forward
Chee is an experienced consultant in the healthcare and life sciences sector
in North America and Asia Pacific, with more than 18 years of experience in
business and operational strategy consulting, leveraging strong market
research capabilities. She has more than 12 years of healthcare experience
specifically in China.
Prior to joining EIU Healthcare, Chee was the Strategy & Change
Pharmaceutical leader in IBM Global Business Services (previously
PricewaterhouseCoopers) in China. Before that, she was with the North
American R&D pharmaceutical industry practice based in Toronto.
Chee has extensive experience working with senior executives of both
healthcare and life sciences companies and government organizations to
develop and implement strategic plans.
Chee focuses on med tech globally, working with global IVD leaders such as
Abbott Diagnostics, Roche Diagnostics, Danaher (i.e. Beckman Coulter, Leica,
Radiometer), Bio-Rad and Sysmex. Chee has managed large scale projects to
provide credible market insights to help clients achieve sustainable growth.
In Asia Pacific, she has worked with other medical technology companies and
research institutes. She has led numerous consulting projects to formulate
winning go-to-market strategies in emerging markets in Asia Pacific and Latin
America.
She has published various white papers and presented at major conferences on
current healthcare topics in Asia. She has covered topics such as “Future
Outlook for Health in China”, “SE Asia: The New Emerging Healthcare Market
Challenge”, “Digital Healthcare”, etc.
Chee holds an MBA from Schulich School of Business, York University (Canada)
and BSc (Hons) in Microbiology from University of Toronto.
2:00 pm -2:45 SGT
NUDGING OR NAGGING? ENCOURAGING CITIZENS TOWARDS GOOD HEALTH
The cost and future sustainability of healthcare systems is a major concern for
Asian governments, and enhanced efficiency and sustainability a constant
priority. When patients are empowered to be part of the decision-making process
around care through initiatives such as health literacy drives, they are also
more likely to build better and more trusting relationships with providers,
driving care continuity and adherence to treatment regimens. Digitisation has
opened the door to remote patient management, better and faster communication,
and more efficient and accessible forms of preventive and curative care. How can
consumer-facing health platforms facilitate faster buy-in and behavioural change
to drive preventive care? How can public health campaigns be used to influence
government policy and personal behaviour to restrict consumption of unhealthy
food and other “vice” items, addressing risk factors for chronic and acute
illnesses? How can leaders in healthcare and the public sector encourage
healthier lifestyles in a sustainable, authentic way? Is this too paternalistic?
* View Profile
NINA GLORIANI
Member, WHO Scientific Steering Committee for COVID-19 Solidarity Vaccines
Trial and Former dean, College of Public Health, University of the
Philippines
bar1 bar2
NINA GLORIANI
Member, WHO Scientific Steering Committee for COVID-19 Solidarity Vaccines
Trial and Former dean, College of Public Health, University of the
Philippines
*
*
November 17th 2022
* 02:00 pm -2:45
Nudging or nagging? Encouraging citizens towards good health
* View Profile
POLLY CHEUNG
Founder, Hong Kong Breast Cancer Foundation
bar1 bar2
POLLY CHEUNG
Founder, Hong Kong Breast Cancer Foundation
November 17th 2022
* 02:00 pm -2:45
Nudging or nagging? Encouraging citizens towards good health
* View Profile
WOO YIN LING
Professor of obstetrics and gynaecology, University of Malaya
bar1 bar2
WOO YIN LING
Professor of obstetrics and gynaecology, University of Malaya
*
*
*
November 17th 2022
* 02:00 pm -2:45
Nudging or nagging? Encouraging citizens towards good health
Woo Yin Ling is a professor of obstetrics and gynaecology at University of
Malaya and a consultant gynaecological oncologist in University Malaya
Medical Centre. She completed her specialist and sub-specialty training in
gynaecological oncology and post-doctoral research degree in the UK and was
conferred her PhD by Cambridge University. Professor Woo has received many
awards for her professional excellence, including the Royal College of
Obstetrician and Gynaecologist Gold Medal and the Cancer Research UK Gordon
Hamilton Fairley Fellowship.
Professor Woo is an international opinion leader in the prevention and
treatment of cervical cancer. She is currently the Malaysian country
representative for the Asia-Oceania Research Organisation in Genital
Infection and Neoplasia (AOGIN), is a member of the Asia-Pacific Economic
Consortium and Commonwealth Task-Force and sits on the educational committee
of the International Papillomavirus Society. Having conceptualised and
executed Programme ROSE, she is now one of the founding trustees of the ROSE
Foundation.
MODERATED BY
* View Profile
GERARD DUNLEAVY
Manager, health policy, Economist Impact
bar1 bar2
GERARD DUNLEAVY
Manager, health policy, Economist Impact
November 17th 2022
* 02:00 pm -2:45
Nudging or nagging? Encouraging citizens towards good health
* 02:50 pm -3:35
Defying disinformation: health in the age of “fake news”
Gerard Dunleavy is a manager in the health policy team at Economist Impact.
He manages global engagements with international clients in the health-care
sector, from conceptualising to delivering and executing customised research
projects. He manages multidisciplinary teams, conducting both quantitative
and qualitative analyses, across a broad range of disease areas and health
policies.
Prior to joining Economist Impact, Mr Dunleavy worked in academic settings
specialising in evidence-based synthesis and epidemiological studies. He
holds a PhD in public health and epidemiology and a master’s degree in health
education and promotion, both from Maastricht University.
2:50 pm -3:35 SGT
DEFYING DISINFORMATION: HEALTH IN THE AGE OF “FAKE NEWS”
Misinformation kills. Joe Rogan’s Spotify podcast has at various times claimed
that covid-19 treatments were concealed by hospital leaders or are a threat to
reproductive health, and that public-health announcements on the subject were
brainwashing, among other falsehoods. Misinformation and its more malicious
sibling, disinformation, divides and distracts us from optimal preventive and
curative healthcare.
Vaccines had been a contentious issue for some even before covid-19, but the
pandemic has politicised them further. Hesitance has led to hundreds of
thousands of preventable deaths globally. Recently, Hong Kong bore the brunt of
an Omicron spike due to deaths amongst the unvaccinated elderly. Despite ongoing
efforts at persuasion—a deluge of data, public-health drives, incentives—and
failing that, vaccine mandates, sceptics remain steadfast. In March 2021 the
Malaysian government outlawed the dissemination of false information related to
the covid-19 pandemic. Is this an erosion of civil liberties or a necessary step
towards population immunity? Where can influential public advocates mitigate
hesitance? What are the ongoing results of disinformation? Which preventive and
curative treatments are most affected? What are the optimal strategies to combat
fake news? How did Singapore drive a successful campaign to vaccinate its
elderly against covid-19?
* View Profile
ALICE BUDISATRIJO
Head of misinformation policy, Asia-Pacific, Meta
bar1 bar2
ALICE BUDISATRIJO
Head of misinformation policy, Asia-Pacific, Meta
*
*
November 17th 2022
* 02:50 pm -3:35
Defying disinformation: health in the age of “fake news”
* View Profile
CLARA JIMÉNEZ CRUZ
Co-founder and chief executive, Maldita.es
bar1 bar2
CLARA JIMÉNEZ CRUZ
Co-founder and chief executive, Maldita.es
*
November 17th 2022
* 02:50 pm -3:35
Defying disinformation: health in the age of “fake news”
Clara Jiménez Cruz is the co-founder and chief executive of Maldita.es, a
Spanish foundation and non-profit news organisation created to fight
disinformation in public discourse through fact-checking and data journalism.
Maldita.es develops tech tools that enable citizens to make informed
decisions. The Maldita.es team also engages with its audience through new
formats, such as its WhatsApp fact-checking chatbot, which won the European
Press Prize in 2020. After a decade-long career as a TV journalist, Ms Cruz,
who works regularly with national media organisations in Spain, was appointed
to the High-Level Group against Disinformation by the European Commission and
is a current member of the advisory board of the International Fact-Checking
Network. Among other recognitions, she has been awarded a 2019 Ashoka
Fellowship and was named Spanish Young Journalist of the Year in 2020. Ms
Cruz is also the co-founder of Factchequeado, a US-based initiative to combat
disinformation among Hispanic communities.
* View Profile
TIM NGUYEN
Head, unit for high-impact events preparedness, World Health Organisation
bar1 bar2
TIM NGUYEN
Head, unit for high-impact events preparedness, World Health Organisation
*
*
November 17th 2022
* 02:50 pm -3:35
Defying disinformation: health in the age of “fake news”
Tim Nguyen is head of the unit for high-impact events in the epidemic and
pandemic preparedness and prevention department of the World Health
Organisation (WHO) Health Emergencies Programme. Mr Nguyen joined WHO in 2006
as a technical officer in the yellow fever programme, which co-ordinated an
initiative funded by GAVI to provide 40m doses of vaccine to populations most
at risk. In 2008, he joined WHO’s Global Influenza Programme and took part in
the global response to the first influenza pandemic of the 21st century. In
2011, Mr Nguyen was the founding member of WHO’s Global Hepatitis Programme
and project manager for the development of the first WHO treatment guideline
for the hepatitis C virus. From 2014 to 2017, he was the unit leader for
knowledge management, evidence and research for policymaking at the WHO
regional office for Europe, based in Copenhagen. There, he established the
scientific journal Public Health Panorama and developed the WHO/Europe
resolution and action plan for evidence-informed policymaking.
MODERATED BY
* View Profile
GERARD DUNLEAVY
Manager, health policy, Economist Impact
bar1 bar2
GERARD DUNLEAVY
Manager, health policy, Economist Impact
November 17th 2022
* 02:00 pm -2:45
Nudging or nagging? Encouraging citizens towards good health
* 02:50 pm -3:35
Defying disinformation: health in the age of “fake news”
Gerard Dunleavy is a manager in the health policy team at Economist Impact.
He manages global engagements with international clients in the health-care
sector, from conceptualising to delivering and executing customised research
projects. He manages multidisciplinary teams, conducting both quantitative
and qualitative analyses, across a broad range of disease areas and health
policies.
Prior to joining Economist Impact, Mr Dunleavy worked in academic settings
specialising in evidence-based synthesis and epidemiological studies. He
holds a PhD in public health and epidemiology and a master’s degree in health
education and promotion, both from Maastricht University.
3:40 pm -4:25 SGT
DECODING GENOMICS: CELL AND GENE THERAPIES
Genomic sequencing has been one of the stars of the covid-19 crisis. The
application of genetics to medicine in a systematic and transformative way
illuminates the pathology of diseases while helping to track, cure and prevent
them. Our increasing understanding of key biological structures at a micro level
has implications for precision health. Now human genomes can be sequenced in
just a few hours. This technology has vast potential—and a much bigger prize
lies ahead. Today’s tech giants are placing bets on the future of gene editing,
and many developments in cell and gene therapy are set to come to fruition
between now and 2025. People’s genomes can be examined for clusters of genes
that raise or lower the risk of specific diseases, with implications for
preventive screening. Genomic surveillance is critical to robust public health
preparedness. Contact tracing, origin discovery and the identification of
variants of concern would be vastly more difficult without current advances in
genetic sequencing. How can healthcare leaders use the expertise honed by
covid-19 to improve the diagnosis and treatment of diseases of every kind? What
issues of accessibility need to be considered? Where does AI play a part in
processing the deluge of data coming from genomics? How can trust be built
between key stakeholders, experts in genomics data and AI systems? What ethical
and legal issues need to be resolved?
* View Profile
PATRICK TAN
Executive director, PRECISE (Precision Health Research, Singapore) and Genome
Institute of Singapore, A*STAR
bar1 bar2
PATRICK TAN
Executive director, PRECISE (Precision Health Research, Singapore) and Genome
Institute of Singapore, A*STAR
November 17th 2022
* 03:40 pm -4:25
Decoding genomics: cell and gene therapies
* View Profile
RICHARD SCOTT
Chief medical officer, Genomics England
bar1 bar2
RICHARD SCOTT
Chief medical officer, Genomics England
November 17th 2022
* 03:40 pm -4:25
Decoding genomics: cell and gene therapies
Richard Scott is chief medical officer at Genomics England. He joined the
organisation in 2015. Dr Scott is also a consultant and honorary associate
professor in clinical genetics at Great Ormond Street Hospital for Children
and the UCL Institute of Child Health, where his practice focuses on
diagnosing children with rare multisystem disorders.
Dr Scott trained in medicine at Cambridge University and University College
London. He specialised in paediatrics and subsequently clinical genetics in
London and completed his PhD on childhood cancer syndromes at the Institute
of Cancer Research. Through his clinical practice and in his role at Genomics
England, he is passionate about harnessing the power of new genomic
technologies for the benefit of all patients in mainstream health care.
* View Profile
SURAKAMETH MAHASIRIMONGKOL
Director, Medical Life Sciences Institute, Department of Medical Sciences,
Ministry of Public Health, Thailand
bar1 bar2
SURAKAMETH MAHASIRIMONGKOL
Director, Medical Life Sciences Institute, Department of Medical Sciences,
Ministry of Public Health, Thailand
November 17th 2022
* 03:40 pm -4:25
Decoding genomics: cell and gene therapies
MODERATED BY
* View Profile
NEELADRI VERMA
Manager, health practice, Economist Impact
bar1 bar2
NEELADRI VERMA
Manager, health practice, Economist Impact
November 17th 2022
* 03:40 pm -4:25
Decoding genomics: cell and gene therapies
Neeladri Verma is a manager in the health practice team at Economist Impact.
She works with international clients in the healthcare sector on global
assignments conceptualising, delivering and executing bespoke research
projects. She engages with multiple stakeholders and manages
multidisciplinary teams, conducting quantitative and qualitative analyses
across health priority themes. Dr Verma has a rich and diverse background in
health and research, focusing primarily on Asian markets. A dental doctor by
trade, she also holds an MBA from the University of Hong Kong. Prior to
joining Economist Impact, she worked as a healthcare consultant at the Asia
Care Group, conducting research and strategic analyses on topics such as
vaccine procurement, the role of the private sector in health reforms, health
system appraisals and multisectoral approaches to health policy.
4:30 pm -5:15 SGT
CONNECTING CLIMATE CHANGE AND CARE: GREEN AND SUSTAINABLE HEALTH
A new IPCC report says the window to meet UN climate targets is vanishing.
Emissions must peak by 2025 to keep global warming well below the 2°C limit.
Even though climate change is the defining crisis of our generation, the
severity of its impact on human health might not be obvious. Natural security is
the task of making societies resilient to risks stemming from their connection
to the living world, including disease, food insecurity, biological warfare and
environmental degradation. Humans put unsustainable demands on the very same
environment their health depends on, exceeding nature’s capacity for
regeneration.
Not adopting aggressive climate policies brings its own costs, including lost
lives, livelihoods and productivity, and destruction caused by extreme weather
events. Ongoing deforestation and biodiversity loss is increasing the risk that
zoonotic diseases will spill over to humans. Is covid-19 a warning of what may
come from encroaching on animal habitats? This panel seeks to explore the rise
in awareness of ESG concerns against the backdrop of the SDGs, and the links
between climate change and common health issues in Asia such as respiratory
disease, heatstroke, malnutrition, waterborne diseases and mental health issues.
What are the major health challenges here? Where can healthcare leaders mitigate
carbon footprints and medical equipment waste? How can we incentivise green
health amid a turbulent global geopolitical landscape where ongoing conflict is
disrupting supply chains and driving inflation?
* View Profile
AKEEM ALI
Head, Asia-Pacific Centre for Environment and Health, World Health
Organisation, Western Pacific Region
bar1 bar2
AKEEM ALI
Head, Asia-Pacific Centre for Environment and Health, World Health
Organisation, Western Pacific Region
*
*
November 17th 2022
* 04:30 pm -5:15
Connecting climate change and care: green and sustainable health
* View Profile
CHEN QIUFAN
Science fiction writer and columnist
bar1 bar2
CHEN QIUFAN
Science fiction writer and columnist
*
*
*
November 17th 2022
* 04:30 pm -5:15
Connecting climate change and care: green and sustainable health
* View Profile
ZULFIQAR BHUTTA
Founding director, Centre of Excellence in Women and Child Health, Aga Khan
University, and co-director, Centre for Global Child Health, Hospital for
Sick Children
bar1 bar2
ZULFIQAR BHUTTA
Founding director, Centre of Excellence in Women and Child Health, Aga Khan
University, and co-director, Centre for Global Child Health, Hospital for
Sick Children
November 17th 2022
* 04:30 pm -5:15
Connecting climate change and care: green and sustainable health
Zulfiqar A Bhutta is the founding director of the Centre of Excellence in
Women and Child Health and the Institute of Global Health and Development,
Aga Khan University. She is also the inaugural Robert Harding Chair in Global
Child Health and co-director of the SickKids Centre for Global Child Health
in Toronto, Canada. Dr Bhutta leads large research groups in Canada, Pakistan
and East Africa focused on scaling up evidence-based interventions in
community settings and implementation of RMNCAH&N (reproductive, maternal,
neonatal, child and adolescent health and nutrition) interventions in
humanitarian contexts. Dr Bhutta is a fellow of the Royal Society and
received the 2021 Institute for Health Metrics and Evaluation Roux Prize for
significant contributions to women and child health research, and she was
recently awarded the John Dirks Canada Gairdner 2022 Global Health Award, one
of the most prestigious awards in global health.
MODERATED BY
* View Profile
SHAILEEN ATWAL
Public health analyst, policy and insights EMEA, Economist Impact
bar1 bar2
SHAILEEN ATWAL
Public health analyst, policy and insights EMEA, Economist Impact
November 17th 2022
* 04:30 pm -5:15
Connecting climate change and care: green and sustainable health
Shaileen Atwal is a public health analyst in the Policy and Insights team at
Economist Impact in London, where she is involved in projects ranging from
Sex and Gender Equity in Brain-disease Research and Digital Health. Prior to
this, she completed her Master’s in Public Health Degree at the University of
Warwick. She has keen interest in the sustainability of food systems and has
conducted research exploring the risk factors associated with farmer suicides
in India and developed a campaign for SUSTAIN to increase the sustainability
of small and medium food enterprises at the Environmental Change Institute,
University of Oxford. Shaileen has a degree in Physiotherapy from St George’s
University of London and started her career specialising in the field of
neurology.
* Upcoming events
* Past events
* Webinars
* About us
* Become a sponsor
KEEP UPDATED
*
*
*
*
*
*
THE ECONOMIST GROUP
* The Economist
* EuroFinance
* Editorial Staff
* Commercial Payments International
* The Economist Store
* Accessibility
* Site index
* Privacy policy
* Cookie info
* Term to use
* Manage Cookie Preferences
Copyright @ The Economist Newspaper Limited 2022 All rights reserved
×
×
CloseReferral Marketing Powered By InviteReferrals